raloxifene hydrochloride has been researched along with tamoxifen in 657 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (2.13) | 18.7374 |
| 1990's | 94 (14.31) | 18.2507 |
| 2000's | 364 (55.40) | 29.6817 |
| 2010's | 163 (24.81) | 24.3611 |
| 2020's | 22 (3.35) | 2.80 |
| Authors | Studies |
|---|---|
| Black, LJ; Clemens, JA; Falcone, JF; Jevnikar, MG; Jones, CD; Peters, MK; Pike, AJ; Thompson, AR | 1 |
| Bryant, HU; Cullinan, GJ; Glasebrook, AL; Hauser, KL; Muehl, BS; Palkowitz, AD; Pell, TR; Phillips, DL; Sato, M; Shetler, PK; Short, LL; Thrasher, KJ | 1 |
| Bischoff, SF; Buhl, T; Floersheim, P; Fournier, B; Halleux, C; Kallen, J; Keller, H; Renaud, J; Schlaeppi, JM; Stark, W | 1 |
| Aikens, C; Eyunni, SVK; Hansberry, TD; Mateeva, N; Nag, A; Ononuju, U; Redda, KK | 1 |
| Bern, HA; Chou, YC; Iguchi, T | 1 |
| Gottardis, MM; Jordan, VC; Satyaswaroop, PG | 1 |
| de Launoit, Y; Dufour, M; Labrie, F; Simard, J; Veilleux, R | 1 |
| Bennett, JA; Bowser, SS; Bradley, L; Dickerman, HW; Gierthy, JF; Lincoln, DW; Roth, KE | 1 |
| Boundy, V; Komm, BS; Lyttle, CR; Sundstrom, SA; Xu, Q | 1 |
| Bauss, F; Feldmann, S; Lempert, UG; Minne, HW; Parvizi, S; Pfeifer, M; Ziegler, R | 1 |
| Dufour, JM; Labrie, F; Levesque, C; Merand, Y; Poirier, D; Poulin, R | 1 |
| Catt, KJ; Knecht, M; Tsai-Morris, CH | 1 |
| Dohanich, GP; McEwen, BS; Meisel, RL; Pfaff, DW | 1 |
| Gottardis, MM; Jordan, VC | 1 |
| Jordan, VC; Lindgren, JU; Phelps, E | 1 |
| Clark, GM; Hobbs, K; Osborne, CK | 1 |
| Bennett, DR; Black, LJ; Clemens, JA; Jones, CD | 1 |
| Jordan, VC | 22 |
| Green, LR; Newboult, E; Valcaccia, B; Wakeling, AE | 1 |
| Babitsky, G; Kleinberg, DL; Todd, J | 1 |
| Valcaccia, B; Wakeling, AE | 1 |
| Black, LJ; Falcone, JF; Jones, CD | 1 |
| Bryant, HU; Cole, HW; Draper, MW; Fuchs-Young, R; Glasebrook, AL; Magee, DE; Rippy, MK; Short, LL; Termine, JD | 1 |
| Draper, MW; Flowers, DE; Huster, WJ; Neild, JA; Zerbe, RL | 1 |
| Clemm, DL; Goldman, ME; Hermann, T; McDonnell, DP; Pike, JW | 1 |
| Arbell, A; Danilenko, M; Karas, M; Kleinman, D; LeRoith, D; Levy, J; Roberts, CT; Sharoni, Y | 1 |
| Hoszowski, K | 1 |
| Bryant, HU; Rippy, MK; Sato, M | 1 |
| Ziegler, J | 1 |
| Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE | 1 |
| Raisz, LG | 1 |
| Fournier, B; Häring, S; Kaye, AM; Sömjen, D | 1 |
| Fuchs-Young, R; Hale, L; Howe, S; Miles, R; Walker, C | 1 |
| Kaye, AM; Sömjen, D; Waisman, A | 1 |
| Gradishar, WJ; Jordan, VC | 1 |
| Carver, JM; Lundeen, SG; McKean, ML; Winneker, RC | 1 |
| Cheskis, BJ; Karathanasis, S; Lyttle, CR | 1 |
| Logie, C; Nichols, M; Rientjes, JM; Stewart, AF | 1 |
| Cosman, F; Lindsay, R | 1 |
| Anthony, MS; Clarkson, TB; Cline, JM; Williams, JK | 1 |
| Rackoff, P | 1 |
| Belanger, A; Gauthier, S; Labrie, C; Labrie, F; Merand, Y; Poirier, D; Sanchez, R; Simard, J; Singh, SM | 1 |
| Asplin, I; Baer, P; Brown, HR; Henke, B; Jones, SA; McDonnell, DP; Morris, DC; Norris, JD; Sauls, H; Wagner, BL; Willson, TM; Wolfe, S | 1 |
| Gustafsson, J; Kuiper, GG; Kushner, PJ; Nilsson, S; Paech, K; Scanlan, TS; Webb, P | 1 |
| Andersson-Ross, C; Barkhem, T; Höglund, M; Nilsson, S | 1 |
| Lane, MV; Merchenthaler, I; Shughrue, PJ | 1 |
| Bryant, HU; Cullinan, GJ; Dodge, JA; Glasebrook, AL; Grese, TA; Jones, CD; Matsumoto, K; Palkowitz, AD; Sato, M; Sluka, JP; Termine, JD; Winter, MA; Yang, NN | 1 |
| Bryant, HU; Dere, WH | 1 |
| Powles, TJ | 5 |
| Jordan, VC; Kwaan, HC; Levenson, AS; Svoboda, KM | 1 |
| Nelson, NJ | 2 |
| Rifkind, BM; Rossouw, JE | 1 |
| Dove, A | 1 |
| Gibbs, WW | 1 |
| Davidson, NE; Hahm, HA; Nass, SJ | 1 |
| McNeil, C | 1 |
| Amir-Zaltsman, Y; Jaffe, A; Knoll, E; Kohen, F; Somjen, D; Stern, N | 1 |
| Funder, JW; Logie, C; Myles, K; Nichols, M; Stewart, AF | 1 |
| Reynolds, T | 1 |
| Goldstein, SR | 6 |
| Overmoyer, BA | 1 |
| Chan, KW; Lim, HK; Sisenwine, S; Stellingweif, S | 1 |
| Gradishar, WJ; Jordan, VC; Morrow, M; Pierce, LJ; Takei, H | 1 |
| Delmas, PD; Fontana, A | 2 |
| Kardinal, CG; Veith, R | 1 |
| Brockie, J | 1 |
| Cohen, FJ; Mitlak, BH | 1 |
| Jordan, VC; Morrow, M | 2 |
| Franks, AL; Steinberg, KK | 1 |
| Fitzpatrick, LA | 1 |
| Carthew, P; Edwards, RE; Nolan, BM | 1 |
| Stephenson, J | 1 |
| Bonn, T; Brzozowski, AM; Carlquist, M; Engström, O; Gustafsson, JA; Hubbard, RE; Ljunggren, J; Pike, AC; Thorsell, AG | 1 |
| Dullaart, RP | 1 |
| Kuter, I | 1 |
| Hart, W; Netelenbos, JC | 1 |
| Christiansen, C | 1 |
| Faglia, G | 1 |
| Dören, M | 1 |
| Agnusdei, D; Iori, N | 1 |
| Zurlinden, J | 1 |
| Gardner, N | 1 |
| Brown, PH; Lippman, SM | 2 |
| Evans, A; Healy, D; Vollenhoven, B | 1 |
| Lush, DT | 1 |
| Chlebowski, RT; Collyar, DE; Pfister, DG; Somerfield, MR | 1 |
| Christensen, DJ; Fowlkes, DM; McDonnell, DP; Nagel, SC; Norris, JD; Paige, LA; Wijayaratne, AL | 1 |
| Eppes, PG; Wilson, CT; Wozniak, TF | 1 |
| Arnaud, CD; Chiu, KM; Roe, EB | 1 |
| Burckhardt, P | 1 |
| Cockcroft, N; Dahllund, J; Härkönen, P; Hemminki, K; Kangas, L; Koskinen, M; Laine, A; Peng, Z; Qu, Q; Väänänen, K; Zheng, H | 1 |
| Minton, SE | 1 |
| Brandi, ML; Fiorelli, G; Martineti, V; Picariello, L; Tonelli, F | 1 |
| Jordan, VC; Levenson, AS | 1 |
| Manni, A | 1 |
| Aberle, S; Fritzemeier, KH; Hegele-Hartung, C; Humm, R; Kauser, K; Knauthe, R; Liu, HL; MacRobbie, J; Ponte, P; Rubanyi, GM; Vergona, R; Webster, L; White, FA; Zajchowski, DA; Zhu, D | 1 |
| Burakov, D; Cheskis, BJ; Freedman, LP; Rachez, C; Wong, CW | 1 |
| Carolin, KA; Pass, HA | 1 |
| Aba, F; Beckmann, MW; Bender, HG; Jap, D; Kuschel, B; Lux, M | 1 |
| Cohen, FJ; Glusman, J; Gradishar, W; Lu, Y; Sledge, GW; Vogel, C | 1 |
| Al-Jamal, JH; Dubin, NH | 1 |
| Bentrem, DJ; Jordan, VC | 3 |
| Cyr, M; Di Paolo, T; Landry, M | 1 |
| Funahashi, H | 2 |
| Cuzick, J | 5 |
| Baker, VL; Jaffe, RB; Leitman, D | 1 |
| Chlebowski, RT | 4 |
| Aguilar, R; Alonso, R; Bellido, C; Garrido-Gracia, JC; González, D; Hernández, G; Sánchez-Criado, JE | 1 |
| Chow, MS; Reddy, P | 1 |
| Mincey, BA; Moraghan, TJ; Perez, EA | 1 |
| O'Regan, RM | 2 |
| Bentrem, DJ; Jordan, VC; Liu, H; MacGregor Schafer, J; Zapf, JW | 1 |
| Hozumi, Y; Jordan, VC; Kawano, M | 1 |
| Fisher, PW; Gowen, M; Nadeau, DP; Nuttall, ME; Stroup, GB; Suva, LJ | 1 |
| Grow, DR; Reece, MT | 1 |
| Fisher, PW; Gowen, M; Nuttall, ME; Suva, LJ | 1 |
| Galid, A; Kubista, E; Seifert, M | 1 |
| Yardley, DA | 1 |
| Anchim, T; Dabrowska, M; Dziecioł, J; Swiatecka, J; Wołczyński, S | 1 |
| Terakawa, N | 1 |
| Osborne, MP; Rosenbaum Smith, SM | 1 |
| Hartmann, LC; Perez, EA; Rhodes, DJ | 1 |
| Fackenthal, JD; Olopade, MD; Olufunmilayo, I | 1 |
| Mamounas, EP | 1 |
| Dalton, RR; Kallab, AM | 1 |
| Jordan, VC; O'Regan, RM | 2 |
| Cyr, M; Di Paolo, T; Landry, M; Morissette, M | 1 |
| Ben-Rafael, Z; Kaplan, B; Nahum, R | 1 |
| Feigelson, HS; Henderson, BE | 1 |
| Fabian, CJ | 1 |
| Dardes, RC; Jordan, VC | 1 |
| Moore, HC | 1 |
| Leris, C; Mokbel, K | 1 |
| Blumenthal, R; Bush, TL; Clarkson, TB; Lobo, R | 1 |
| Fuqua, SA; Russo, J; Shackney, SE; Stearns, ME | 1 |
| Perrone, A; Tinelli, A; Tinelli, FG | 1 |
| Deb Los Reyes, A; Jordan, VC; Lee, ES; Liu, H; Zapf, JW | 1 |
| Eiken, PA; Kønig, KB; Schwarz, P | 1 |
| Feher, M; Labute, P; Schmidt, JM; Sourial, E; Williams, C | 1 |
| Clegg, NJ; Scanlan, TS; Weatherman, RV | 1 |
| Tan-Chiu, E; Wickerham, DL | 1 |
| Cyr, M; Di Paolo, T; Landry, M; Morissette, M; Thibault, C | 1 |
| Swain, SM | 1 |
| Feightner, J; Levine, M; Moutquin, JM; Walton, R | 1 |
| Gescher, AJ; O'Byrne, KJ; Sharma, RA; Steward, WP | 1 |
| Neven, P; Vergote, I | 1 |
| Butterworth, M; Greaves, P; Green, A; Parrott, E; White, IN | 1 |
| Dhingra, K | 1 |
| Consler, TG; Gray, JG; Iannone, MA; Parks, DJ; Pearce, KH; Stimmel, JB | 1 |
| Mincey, BA | 1 |
| Butterworth, M; Greaves, P; Green, AR; Jones, PS; Parrott, EL; White, IN | 1 |
| Hartmann, L; Nelson, W; Stefanek, M | 1 |
| Allan, GF; Clancy, J; Hutchins, A; Liu, X | 1 |
| Kato, S; Suzawa, M; Wada, O; Yamamoto, Y; Yanagisawa, J; Yano, T; Yogiashi, Y | 1 |
| Gapstur, S; Jordan, VC; Morrow, M | 1 |
| Gradishar, WJ; O'Regan, RM | 1 |
| Lorraine, J | 1 |
| Bloss, JD; Rodabaugh, KJ | 1 |
| Carroll, DC; Scanlan, TS; Weatherman, RV | 1 |
| Bentrem, DJ; Jordan, VC; Liu, H; Loweth, JA; McKian, KP; Park, WC; Reyes, Ade L; Schafer, JM; Zapf, JW | 1 |
| Bevers, TB | 3 |
| Ang, WC; Farrell, E; Vollenhoven, B | 1 |
| Bentrem, DJ; Jordan, VC; O'Regan, RM | 1 |
| Dickler, MN; Norton, L | 1 |
| Walsh, BW | 1 |
| Sherman, S | 1 |
| Dunn, BK; Wolmark, N | 1 |
| Benson, JR | 1 |
| Bury, PS; Clarke, CH; Cunningham, KA; de Beun, R; Koldzic-Zivanovic, N; Thomas, ML; Wassermann, K; Zhou, W | 1 |
| Jordan, VC; Park, WC | 1 |
| Duvernoy, CS; Mosca, L | 1 |
| Sporn, MB | 1 |
| Dardes, RC; De Los Reyes, A; Gajdos, C; Jordan, VC; O'Regan, RM; Park, W; Rademaker, AW | 1 |
| Fentiman, IS; Salih, AK | 1 |
| Arici, A; Garcia-Velasco, JA; Pehlivan, T; Selam, B; Seli, E | 1 |
| Aguilar, E; Barreiro, ML; Gonzalez, LC; Pinilla, L; Tena-Sempere, M | 1 |
| Gajdos, C; Jordan, VC | 1 |
| Kearney, CE; Purdie, DW | 1 |
| Bryant, HU; Ciaccia, AV; Silfen, SL | 1 |
| Zujewski, J | 1 |
| Katzenellenbogen, BS; Katzenellenbogen, JA | 1 |
| Brown, M; Shang, Y | 1 |
| Fabian, CJ; Kimler, BF | 2 |
| Twombly, R | 1 |
| Rhodes, DJ | 1 |
| Bentrem, DJ; Craig Jordan, V | 1 |
| Grady, D | 1 |
| Candas, B; Couillard, S; Gutman, M; Labrie, C; Labrie, F; Roy, J | 1 |
| Blau, R; Lower, EE; Rohatgi, N | 1 |
| Alaoui-Jamali, M; Anghel, SI; Barsalou, A; Dayan, G; Mader, S; Van de Velde, P | 1 |
| Anthony, M; Arun, B; Dunn, B | 1 |
| Chen, B; Dardes, RC; Jordan, VC; Osipo, C; Pearce, ST; Schafer, JM | 1 |
| Bentrem, D; Dardes, RC; De Los Reyes, A; Gajdos, C; Jordan, VC; O'Regan, RM; Robinson, SP | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
| Aliau, S; Bonnafous, JC; Borgna, JL; Mattras, H; Richard, E | 1 |
| Harris, R; Kinsinger, LS; Lohr, KN; Sox, HC; Woolf, SH | 1 |
| Bradbury, J | 1 |
| Costantino, JP; Cronin, WM; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Chan, S | 1 |
| Burstein, HJ; Chlebowski, RT; Col, N; Collyar, DE; Cummings, SR; Eisen, A; Lipkus, I; Pfister, DG; Vogel, VG; Winer, EP | 1 |
| Nagykálnai, T | 1 |
| Brown, HA; Eisen, SF | 1 |
| Obrero, M; Shapiro, DJ; Yu, DV | 1 |
| Cox, DA; Hurn, PD; Littleton-Kearney, MT; Ostrowski, NL; Rossberg, MI | 1 |
| Lopes, P; Trémollières, F | 1 |
| Grümmer, R; Heikaus, S; Traub, O; Winterhager, E | 1 |
| Hindle, WH | 1 |
| Andrade, PM; Baracat, EC; Borra, RC; Lima, GR; Silva, ID | 1 |
| Wickerham, DL | 1 |
| Di Paolo, T; Landry, M; Lévesque, D | 1 |
| Kelminski, A | 1 |
| Kushner, PJ; Nguyen, P; Webb, P | 1 |
| Burd, CJ; Feng, Y; Khan, SA; Singleton, DW | 1 |
| Baker, RS; Clark, KE; Kopernik, G; Mershon, JL; Zoma, WD | 1 |
| Chlebowski, RT; McTiernan, A | 1 |
| Menikoff, J | 1 |
| Rollins, G | 1 |
| Costantino, JP; Cronin, WM; Vogel, VG; Wickerham, DL | 1 |
| Jordan, VC; Pappas, SG | 1 |
| Andersson, G; Dartsch, C; Kack, H; Knappenberger, KS; Liu, J; Nilsson, E; Scott, CW | 1 |
| Ashley, S; Boyle, P; Cuzick, J; Edwards, R; Forbes, J; Powles, T; Veronesi, U | 1 |
| Edwards, RE; Greaves, P; Green, AR; White, IN | 1 |
| Hartmann, LC; Riggs, BL | 1 |
| Blackwood, A; Calzone, K; Domchek, SM; Eisen, A; Stopfer, J; Weber, BL | 1 |
| Di Paolo, T; Landry, M | 1 |
| Runowicz, CD | 1 |
| Bianco, NR; Montano, MM; Perry, G; Smith, MA; Templeton, DJ | 1 |
| Kahán, Z; Thurzó, L | 1 |
| Abrams, J; Deighton-Collins, S; Koide, A; Koide, S; Martinez, A; Schwartz, JA; Skafar, DF; Zhao, C | 1 |
| Touraine, P | 1 |
| Berg, AO | 1 |
| Eriksson, B; Eriksson, H; Muravitskaya, N; Sahlin, L; Stygar, D | 1 |
| Fabris, V; Helguero, LA; Lamb, CA; Lanari, C; Lucas, C; Molinolo, AA | 1 |
| Mortimer, JE; Urban, JH | 1 |
| Evans, DG; Howell, A; Howell, SJ | 2 |
| Dijkstra, B; Hill, AD; McDermott, EW; O'Higgins, NJ; Prichard, RS | 1 |
| Cosman, F; Lindsay, R; Mikhail, M; Nieves, J; Richart, RM; Scotti, RJ; Vardy, MD; Zion, M | 1 |
| Kafka, A; Kreienberg, R | 1 |
| Höffken, K; Sayer, HG | 1 |
| Bergh, J | 1 |
| Cosman, F | 1 |
| Goss, PE; Strassmer-Weippl, K | 1 |
| Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I | 1 |
| Hayes, DF | 1 |
| Smith, RE | 1 |
| Bonanni, B; Cazzaniga, M; Decensi, A; Galli, A; Gonzaga, AG; Serrano, D | 1 |
| Lonard, DM; O'Malley, BW; Tsai, SY | 1 |
| Lo, SS; Vogel, VG | 1 |
| Oh, AS; Reiter, R; Riegel, AT; Wellstein, A | 1 |
| An, J; Christy, RJ; Cvoro, A; Leitman, DC; Rogatsky, I; Tee, MK; Tzagarakis-Foster, C; Yamamoto, KR | 1 |
| Guyot, B; This, P | 1 |
| Kammerer, S | 1 |
| Beckmann, MW; Bender, HG; Dall, P; Djahansouzi, S; Hanstein, B | 1 |
| Costa, A; Decensi, A; Perego, E; Serrano, D | 1 |
| Ricart, JJ | 1 |
| Bryant, K; Costantino, J; Martino, S; McNabb, M; Mershon, J; Powles, T; Secrest, RJ | 1 |
| Frasor, J; Katzenellenbogen, BS | 1 |
| Balaguer, P; Bonnet, S; Cavaillès, V; Duong, V; Escande, A; Margueron, R; Vignon, F | 1 |
| Härkönen, PL; Kangas, L; Zheng, H | 1 |
| Balasenthil, S; Mishra, SK; Nguyen, D; Vadlamudi, RK | 1 |
| Barone, G; Bollati, A; Bonfanti, C; Burattin, A; Cozzi, R; Giustina, A; Poiesi, C; Tulipano, G; Turazzi, S; Valle, D | 1 |
| Czarnocki, KJ; Haczynski, J; Jakimiuk, AJ; Jakowicki, J; Jarzabek, K; Magoffin, DA; Tarkowski, R; Wolczynski, S; Ziegert, M | 1 |
| Flaig, R; Greschik, H; Moras, D; Renaud, JP | 1 |
| Chee, YC | 1 |
| Bhagwat, SS; Brady, H; Doubleday, M; Gayo, L; Hickman, M; Jalluri, RK; Khammungkhune, S; Kois, A; McKie, JA; Mortensen, D; Richard, N; Sapienza, J; Shevlin, G; Stein, B; Sutherland, M | 1 |
| Faught, KA; Lawrence, SE; Lawson, ML; Vethamuthu, J | 1 |
| Haczynski, J; Jarzabek, K; Knapp, P; Koda, M; Sulkowski, S; Wolczynski, S | 1 |
| Hussain, SA; Rea, DW; Stevens, A; Williams, S | 1 |
| Häyry, P; Kangas, L; Luoto, NM; Savolainen-Peltonen, H | 1 |
| Di Paolo, T; Le Saux, M | 2 |
| Izutsu, T; Sugiyama, T | 1 |
| Allan, G; D'Andrea, MR; Guo, JZ; Haynes-Johnson, D; Lawrence, D; Lundeen, S; Pacia, E; Tynan, S | 1 |
| Kurebayashi, J | 1 |
| Nozaki, M | 2 |
| Dosik, M; Kaufman, R | 1 |
| Benvenuti, S; Franceschi, E; Gelmini, S; Luciani, P; Peri, A; Serio, M; Vannelli, GB | 1 |
| Carmichael, PL; Gold, LI; Huby, R; Orton, T; Pole, JC | 1 |
| Aldrighi, JM; Franchini Ramires, JA; Kallás Hueb, C; Kallás, E | 1 |
| Dunn, BK; Ford, LG; Wickerham, DL | 1 |
| Aguilar, R; Bellido, C; de Las Mulas, JM; Garrido-Gracia, JC; Sánchez-Criado, JE | 1 |
| Aoyagi, Y; Asao, T; Buzdar, AU; Hashimoto, A; Sato, K; Shibata, J; Terada, T; Wierzba, K; Yamamoto, Y; Yano, S; Yonekura, K | 1 |
| Chen, Z; Edusa, V; Fadiel, A; Fishman, DA; Naftolin, F; Sakamoto, H; So, J; Song, J | 1 |
| Mijatovic, V; van der Mooren, MJ; Vogelvang, TE | 1 |
| de la Piedra, C; García-Moreno, C; Méndez-Dávila, C; Turbì, C | 1 |
| DeGregorio, MW; Erkkola, R; Härkönen, P; Kivinen, S; Komi, J; Lankinen, KS; Tuimala, R; Vihko, K; Vihtamäki, T; Voipio, S; Ylikorkala, O | 1 |
| Surowiak, P; Zabel, M; Zasławski, R | 1 |
| Czerny, B; Juzyszyn, Z; Myśliwiec, Z; Pawlik, A; Teister, M | 2 |
| Malozowski, S | 1 |
| Baz-Hecht, M; Cosman, F; Cruz, JD; Cushman, M; Lindsay, R; Nieves, JW; Vardy, MD; Zion, M | 1 |
| Huuskonen, J; Nuutinen, T; Ojala, J; Salminen, A; Suuronen, T; Thornell, A | 1 |
| Johansen, AM | 1 |
| Chen, B; Dardes, R; Dowsett, M; Gajdos, C; Johnston, SR; Jordan, VC; Kidwai, N | 1 |
| Herrington, DM; Lakoski, SG | 1 |
| Kovats, S; Mao, A; Nalbandian, G; Nale, S; Paharkova-Vatchkova, V | 1 |
| Beckett, LA; Degregorio, MW; Gregg, JP; Marchisano-Karpman, C; Read, KC; Wurz, GT; Yu, Q | 1 |
| Fischer, PA; Peekhaus, NT; Schneeweis, JE; Shi, X; Strulovici, B; Zheng, W | 1 |
| Blok, LJ; Burger, CW; Gielen, SC; Hanifi-Moghaddam, P; Kühne, LC | 1 |
| Altschuler, A; Somkin, CP | 1 |
| Benjamins, JA; Deighton-Collins, S; Guzmán, CB; Kleerekoper, M; Martinez, A; Skafar, DF; Zhao, C | 1 |
| Ariazi, EA; Glidewell-Kenney, C; Ishikawa, T; Jameson, JL; Lee, EJ; Pillai, S; Weiss, J | 1 |
| Teppa Garrán, AD; Terán Dávila, J | 1 |
| Falany, CN; Falany, JL; Leyh, TS; Pilloff, DE | 1 |
| Franke, HR; Vermes, I; Werner, HM | 1 |
| Des Jarlais, G; Gregorich, SE; Haas, JS; Kaplan, CP; Kerlikowske, K; Pérez-Stable, EJ; Somkin, C | 1 |
| Leitão, A; Menezes, IR; Montanari, CA | 1 |
| Dodwell, D; Johnston, S; Wardley, A | 1 |
| Cuzick, J; Dixon, JM; Houssami, N | 1 |
| Arici, A; Cakmak, H; Kayisli, UA; Seval, Y | 1 |
| Cyrus-David, MS | 1 |
| Clarke, R; Dai, P; Lou, MA; Lu, JF; Nazarov, V; Wong, LJ | 1 |
| Anghel, SI; Auger, A; Croisetière, S; Dayan, G; Katzenellenbogen, JA; Lupien, M; Mader, S; Rocha, W | 1 |
| Gorman, C | 1 |
| Audran, M; Chappard, D; Hoppé, E; Legrand, E | 1 |
| Ayala, GE; Hsieh, JT; Jian, W; Kim, IY; Lerner, SP; Shen, SS; Smith, CL; Sonpavde, G; Younes, M; Yu, J | 1 |
| Cella, D; Gradishar, WJ | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Costantino, JP; Dakhil, S; Ganz, PA; Land, SR; Lee, M; Lockhart, JB; Pajon, ER; Ritter, MW; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Vastag, B | 1 |
| Knox, AS; Lloyd, DG; Meegan, MJ; O'Sullivan, T; Smith, HM; Zisterer, DM | 1 |
| Irth, H; Kool, J; Niessen, WM; van Elswijk, DE; van Liempd, SM; Vermeulen, NP | 1 |
| DeGregorio, M; Erkkola, R; Halonen, K; Heikkinen, J; Komi, J; Lammintausta, R; Lankinen, KS; Saarikoski, S; Tuppurainen, M; Väänänen, K; Ylikorkala, O | 1 |
| Narod, SA | 1 |
| Fourchotte, V; Wickerham, DL | 1 |
| Kozakiewicz, K; Wycisk, A | 1 |
| Johnson, KA | 1 |
| Szabo, E | 1 |
| Brown, PH; Uray, IP | 1 |
| Diez-Perez, A | 1 |
| Asselin, E; Bélanger, G; Boucher, V; Déry, MC; Leblanc, K; Parent, S; Sexton, E | 1 |
| Brown, KH; Cline, JM; Hutchison, J; Lees, CJ; Lundeen, S; Register, TC; Sikoski, P | 1 |
| Brce, J; Doyle, N; Ho, KK; Lee, HJ; Leong, GM; Leung, KC; Sjögren, K | 1 |
| Botsis, DC; Christodoulakos, GE; Lambrinoudaki, IV | 1 |
| Gold, DT; Silverman, SL | 1 |
| Marzo Castillejo, M | 1 |
| Cummings, SR | 1 |
| Altobelli, G; Biglia, N; Cicatiello, L; Cimino, D; De Bortoli, M; Friard, O; Fuso, L; Ponzone, R; Ravo, M; Scafoglio, C; Sismondi, P; Weisz, A | 1 |
| Jaffe, RB; Leitman, DC; Levy, N; Speed, TP; Tang, H; Zhao, X | 1 |
| Fink, G; Fritzemeier, KH; Grant, KE; Hegele-Hartung, Ch; Rosie, R; Sumner, BE | 1 |
| Dunn, BK; Ford, LG | 1 |
| Härkönen, PL; Hentunen, TA; Kangas, L; Michael, H; Väänänen, HK | 1 |
| Jordan, VC; Sharma, CG; Swaby, RF | 1 |
| Chen, WY; Colditz, GA; Rosner, B | 1 |
| Cooperwood, JS; Khan, MO; Musa, MA | 1 |
| Armstrong, K; Micco, E; Tjia, J | 1 |
| Col, NF; Matloff, ET; Moyer, A; Shannon, KM | 1 |
| Jian, W; Lerner, SP; Okuno, N; Shen, SS; Smith, CL; Sonpavde, G; Weiss, H; Younes, M; Yu, J | 1 |
| Mead, MN | 1 |
| Chan, YC; Huang, Y; Leung, FP; Leung, HS; Tsang, SY; Wong, CM; Yao, X; Yung, LM | 1 |
| Aumiller, J | 1 |
| Rubinstein, WS | 1 |
| Chao, HT; Wang, PH | 2 |
| Labrie, F | 1 |
| Taguchi, T | 1 |
| Asaga, S; Jinno, H; Kitajima, M; Sakata, M | 1 |
| Sakemi, H | 1 |
| Kluft, C | 1 |
| Schagen, SB; Schilder, CM | 1 |
| Ball, LJ; Herber, CB; Leitman, DC; Levy, N; Sargeant, T; Speed, TP; Summers, J; Tang, H; Tatomer, D; Zhao, X | 1 |
| Ashcroft, GS; Campbell, L; Emmerson, E; Hardman, MJ | 1 |
| Fabian, C | 1 |
| Anderson, GL; Bernstein, L; Bondy, M; Costantino, JP; Gail, MH; Malone, KE; Marchbanks, PA; McCaskill-Stevens, W; Newman, L; Norman, SA; Pee, D; Selvan, M; Simon, MS; Spirtas, R; Ursin, G | 1 |
| de Castella, A; Gavrilidis, E; Gilbert, H; Gurvich, C; Kulkarni, J; Marston, N; Mehmedbegovic, F; Mu, L | 1 |
| Ainsworth, P; Birenbaum-Carmeli, D; Couch, F; Domchek, S; Foulkes, WD; Friedman, E; Ghadirian, P; Gronwald, J; Kim-Sing, C; Klijn, J; Lubinski, J; Lynch, H; Manoukian, S; Metcalfe, KA; Moller, P; Narod, SA; Rosen, B; Sun, P; Tung, N; Wagner, T | 1 |
| Reeder, JG; Vogel, VG | 1 |
| Bielawski, T; Miltyk, W; Palka, J; Surazynski, A; Wolczynski, S; Zbucka, M | 1 |
| Castrellon, AB; Glück, S | 1 |
| Chao, HT; Cheng, MH; Lee, WL; Wang, PH | 1 |
| Yin, CS | 1 |
| Guo, T; Härkönen, P; Kallio, A; Kangas, L; Lamminen, E; Seppänen, J; Väänänen, HK | 1 |
| Carrero, P; Diz-Chaves, Y; Garcia-Segura, LM; Pernia, O; Tapia-Gonzalez, S | 1 |
| Brentani, MM; Nagai, MA | 1 |
| Vogel, VG | 3 |
| Bläuer, M; Heinonen, PK; Rovio, P; Ylikomi, T | 1 |
| Neves-E-Castro, M | 1 |
| Farmakiotis, D; Katsikis, I; Kourtis, A; Panidis, D; Salmas, M; Tsourdi, E | 1 |
| Berlin, JA; Berlin, M; Bunin, GR; Burgh, D; DeMichele, A; Rebbeck, TR; Rubin, SC; Schinnar, R; Strom, BL; Troxel, AB; Turzo, E; Weber, AL | 1 |
| Howell, A | 1 |
| Kolesar, JM; Thomsen, A | 1 |
| Bebo, BF; Dehghani, B; Foster, S; Kurniawan, A; Lopez, FJ; Sherman, LS | 1 |
| Ball, LJ; Cohen, I; Firestone, GL; Griffin, C; Leitman, DC; Levy, N; Ricke, WA; Speed, TP; Tagliaferri, M; Zhao, X | 1 |
| Hoshi, SL; Kondo, M; Toi, M | 2 |
| Baird, JP; Fudge, MA; Kavaliers, M; Ossenkopp, KP | 1 |
| Dai, H; Wang, B; Zhang, J; Zhang, P; Zhao, S | 1 |
| Cecchini, RS; Costantino, JP; Cronin, WM; Ford, LG; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Bauer, S; Browner, WS; Cummings, SR; Cuzick, J; Kerlikowske, K; Shepherd, J; Smith-Bindman, R; Tice, JA; Vachon, C; Vogel, V; Ziv, E | 1 |
| Akahira, J; Hata, S; Miki, Y; Nagasaki, S; Sasano, H; Suzuki, T | 1 |
| Dieli-Conwright, CM; Rice, JC; Spektor, TM; Todd Schroeder, E | 1 |
| Cutuli, B; Kerbrat, P; Lesur, A; Namer, M | 1 |
| Sharpe, DT; Stevenson, S; Thornton, MJ | 1 |
| Arun, B; Brown, P; Chlebowski, RT; Col, NF; Collyar, D; Cuzick, J; Garber, J; Hagerty, K; Hurley, P; Kramer, BS; Lippman, SM; Morrow, M; Pritchard, KI; Ropka, M; Runowicz, C; Visvanathan, K; Vogel, VG; Wade, JL | 1 |
| Jordan, VC; Peng, J; Sengupta, S | 1 |
| Flamini, MI; Genazzani, AR; Goglia, L; Sanchez, AM; Simoncini, T; Tosi, V | 1 |
| Goel, AJ; Majumdar, SK | 1 |
| Aréchiga-Figueroa, IA; Ferrer, T; López-Izquierdo, A; Ponce-Balbuena, D; Rodríguez-Menchaca, AA; Sánchez-Chapula, JA | 1 |
| Nose, T; Shimohigashi, Y; Tokunaga, T | 1 |
| Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G | 1 |
| Temin, S | 1 |
| Bevers, TB; Coker, L; Hogan, P; Legault, C; Maki, PM; Resnick, SM; Shumaker, SA | 1 |
| Decensi, A; Puntoni, M | 1 |
| Azcoitia, I; Barreto, G; Carrero, P; Diz-Chaves, Y; Garcia-Segura, LM; Pernía, O; Santos-Galindo, M | 1 |
| de Villiers, TJ | 1 |
| Imai, M; Kanzaki, H; Nakajima, T; Okada, H; Tsutsumi, A; Yasuda, K | 1 |
| Lewiecki, EM | 1 |
| Ariazi, EA; Jordan, VC; Kim, H; Lewis-Wambi, JS; Patel, RR | 1 |
| Fu, R; Griffin, JC; Humphrey, L; Nelson, HD; Nygren, P; Smith, ME | 1 |
| Carvalho, DP; de Araujo, LF; de Carvalho, JJ; dos Santos Pereira, MJ; Grozovsky, R; Vaisman, M | 1 |
| Barad, DH; Bevers, TB; Coker, LH; Espeland, MA; Gaussoin, SA; Lane, DS; Limacher, M; Maki, PM; Rapp, SR; Resnick, SM; Shumaker, SA; Stefanick, ML | 1 |
| Becker, C | 1 |
| Biserni, A; Caruso, D; Ciana, P; Horner, D; Komm, B; Maggi, A; Ramachandran, B; Rando, G | 1 |
| Nattinger, AB | 1 |
| Goldstein, RE; Klinge, CM; Kumar, A | 1 |
| Kaufmann, Y; Klimberg, VS; Luo, S; Todorova, VK | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Moore, CD; Reilly, CA; Yost, GS | 1 |
| Dahm, L; Gonzalez-Algaba, A; Klugmann, F; Reuss, B | 1 |
| Chen, LF; Du, XL; Ma, HS; Ma, YX; Shi, JD; Yang, R; Yang, ZP; Zhang, J; Zhou, Y; Zhu, Y | 1 |
| Brown, PH; Hortobagyi, GN | 1 |
| Ravdin, PM | 1 |
| Boudot, A; Flouriot, G; Habauzit, D; Kerdivel, G; Pakdel, F | 1 |
| Bain, C; Hagen, S; Ismail, SI | 1 |
| Birzniece, V; Ho, KK; Sata, A; Sutanto, S | 1 |
| Kane, RL; Shamilyan, T; Tuttle, TM; Virnig, BA; Wang, SY | 1 |
| Clarfeld, RB; Costantino, JP; Grant, MD; McCaskill-Stevens, W; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Schmidt, C | 2 |
| Arevalo, MA; Azcoitia, I; Garcia-Segura, LM; Lagunas, N; Santos-Galindo, M | 1 |
| Archer, DF | 1 |
| da Silva, BB; Rosal, MA | 1 |
| Ashcroft, FJ; Jones, ED; Mancini, MA; Mikic, I; Newberg, JY | 1 |
| Axelrod, D; Kleinberg, D; Singh, B; Smith, J | 1 |
| Cooperwood, JS; Khan, MO; Musa, MA; Rahman, T | 1 |
| Cheong, SJ; Jang, D; Jeong, HJ; Katzenellenbogen, JA; Kim, DW; Lim, ST; Sohn, MH | 1 |
| Calmarza-Font, I; Garcia-Segura, LM; Grassi, D; Lagunas, N | 1 |
| Clarke, BL; Khosla, S | 1 |
| Allen, DM; Almanza, MA; Botello, AM; Grigsby, JG; Mondragon, AA; Parvathaneni, K; Tsin, AT | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Alford, SH; Dillard, AJ; Fagerlin, A; Greene, S; Hayes, DF; McClure, JB; Nair, V; Pitsch, R; Smith, DM; Ubel, PA; Wiese, C; Zikmund-Fisher, BJ | 1 |
| Anderson, GL; Costantino, JP; Freedman, AN; Gail, MH; Graubard, BI; McCaskill-Stevens, W; Vogel, VG; Yu, B | 1 |
| Amir, E; Goodwin, PJ | 1 |
| Arevalo, MA; Bellini, MJ; Diz-Chaves, Y; Garcia-Segura, LM; Santos-Galindo, M | 1 |
| Diaz-Arrastia, CR; Saeed, M; Salama, SA; Salih, SM; Theiler, SK; Veenstra, TD; Williams-Brown, MY; Xu, X | 1 |
| Bergamaschi, A; Katzenellenbogen, BS | 1 |
| Azambuja, E; Bozovic-Spasojevic, I; Cardoso, F; Dinh, P; McCaskill-Stevens, W | 1 |
| Cecchini, RS; Costantino, JP; Cronin, WM; Ford, LG; Runowicz, CD; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Ames, MM; Batzler, A; Carlson, EE; Costantino, JP; Flockhart, DA; Goetz, MP; Ingle, JN; Kubo, M; Mushiroda, T; Nakamura, Y; Paik, S; Safgren, S; Schaid, DJ; Vogel, VG; Weinshilboum, RM; Wickerham, DL; Wolmark, N | 1 |
| da Silva, BB; Dos Santos, AR; Lopes Costa, PV; Rodrigues Junior, DM | 1 |
| Gambhir, SS; Katzenellenbogen, JA; Massoud, TF; Paulmurugan, R; Tamrazi, A | 1 |
| Calmarza-Font, I; Garcia-Segura, LM; Lagunas, N | 1 |
| Klinge, CM; Mattingly, KA | 1 |
| Creasman, WT | 1 |
| Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL | 1 |
| Feria-Velasco, A; Garcia-Segura, LM; González-Burgos, I; Rivera-Cervantes, MC; Velázquez-Zamora, DA | 1 |
| Alencar, AP; Cavalcante, AA; da Silva, BB; dos Santos, AR; Lopes-Costa, PV; Rodrigues, DM | 1 |
| Garcia-Segura, LM; González-Burgos, I; Velázquez-Zamora, DA | 1 |
| Baz-Hecht, M; Cosman, F; Kulak, CA; Lindsay, R; Nieves, J; Shen, V | 1 |
| Gabriel, EM; Jatoi, I | 1 |
| Cauley, JA; Cecchini, RS; Costantino, JP; Cronin, WM; Land, SR; Weissfeld, JL; Wickerham, DL; Wolmark, N | 1 |
| Birzniece, V; Ho, KK; Sutanto, S | 1 |
| Li, Z; Liu, F; Vuki, M; Wu, D; Xu, D; Yan, M; Zhang, L; Zhong, W | 1 |
| Freedman, AN; McNeel, TS; Stevens, WM; Waters, EA | 1 |
| Belleau, P; Calvo, E; Labrie, F; Luu-The, V; Martel, C | 1 |
| Endo, S; Fukami, T; Higuchi, S; Miyashita, T; Nakajima, M; Toyoda, Y; Tsukui, T; Tsuneyama, K; Yokoi, T; Yoshikawa, Y | 1 |
| Kolesar, JM; Simondsen, K; Zhang, Y | 1 |
| Hoffman, KL; Lerner, SP; Smith, CL | 1 |
| Cuzick, J; Sestak, I | 1 |
| Bandos, H; Cauley, JA; Cecchini, RS; Costantino, JP; Cronin, WM; Weissfeld, JL; Wickerham, DL; Wolmark, N | 1 |
| Belli, AK; Buckley, JM; Coopey, SB; Gadd, MA; Garber, JE; Guidi, AJ; Hughes, KS; Kim, EM; Mazzola, E; Parmigiani, G; Polubriaginof, F; Roche, CA; Sharko, J; Smith, BL; Specht, MC | 1 |
| da Silva, BB; dos Santos, AR; Lopes-Costa, PV; Rodrigues-Junior, DM | 1 |
| Ansar, A; Hussey, DJ; Sukocheva, OA; Watson, DI; Wee, C | 1 |
| Avis, NE; Bandos, H; Coker, LH; Costantino, J; Danhauer, SC; Kidwell, K; Legault, C; Naughton, M; Naylor, C; Rapp, S; Shumaker, S; Terracciano, A; Vaughan, L | 1 |
| Cook, ED; Edwards, CL; Figueroa-Moseley, CD; Gibson, RV; McCaskill-Stevens, W; McElwain, DL; Paskett, ED; Roberson, NL; Wickerham, DL; Wilson, JW; Wolmark, N | 1 |
| Ingle, JN; Jenkins, GD; Schaid, DJ; Weinshilboum, RM | 1 |
| Banegas, MP; Barlow, WE; Fagerlin, A; Greene, SM; McClure, JB; Smith, DM; Ubel, PA; Zikmund-Fisher, BJ | 1 |
| Han, SJ; Liu, S; Smith, CL | 1 |
| Fu, R; Griffin, JC; Nelson, HD; Smith, ME | 1 |
| McCarthy, M | 1 |
| Molloy, ME; Perez White, B; Tonetti, DA; Zhang, Y; Zhao, H | 1 |
| Ingle, JN | 1 |
| Kari, S; Lammintausta, R; Unkila, M; Yatkin, E | 1 |
| Ames, MM; Batzler, A; Carlson, EE; Costantino, JP; Flockhart, DA; Goetz, MP; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Paik, S; Schaid, DJ; Vogel, VG; Wang, L; Weinshilboum, RM; Wickerham, DL; Wolmark, N | 1 |
| Pinkerton, JV; Stanczyk, FZ | 1 |
| Bassi, F; Bonanni, B; Brenelli, F; Cazzaniga, M; DeCensi, A; Feroce, I; Gandini, S; Gjerde, J; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Lien, E; Luini, A; Macis, D; Pruneri, G; Sandri, M; Serrano, D; Varricchio, C | 1 |
| Wise, J | 1 |
| Alford, SH; Fagerlin, A; Fuhrel-Forbis, A; Greene, SM; Korfage, IJ; McClure, JB; Smith, DM; Ubel, PA; Zikmund-Fisher, BJ | 1 |
| Moyer, VA | 1 |
| Acaroglu, E; Akel, I; Dede, O; Demirkiran, G; Marcucio, R; Yalcin, N | 1 |
| Crippa, V; Messi, E; Piccolella, M; Poletti, A; Tetel, MJ | 1 |
| Asp, ML; Martindale, JJ; Metzger, JM | 1 |
| Atkinson, HH; Bandos, H; Costantino, JP; Espeland, MA; Geiger, AM; Klepin, HD; Lawrence, JA; Rapp, SR; Sink, KM | 1 |
| Pinkerton, JV; Thomas, S | 1 |
| Hachisuga, T; Inagaki, H; Kawagoe, T; Obara, G; Takahashi, K; Toyohira, Y; Tsutsui, M; Ueno, S; Yanagihara, N | 1 |
| Bolton, JL; Chandrasena, RE; Choi, J; Hemachandra, LP; Michalsen, BT; Patel, H; Piyankarage, SC; Scism, RA; Siklos, MI; Thatcher, GR; Thayer, EN; Wang, S; Wang, Y; Xiong, R | 1 |
| Brann, DW; de Sevilla, L; Khan, MM; Wakade, C | 1 |
| Carly, B; Guzy, L; Kang, X; Liebens, F; Lienart, V; Sajovitz, AM | 1 |
| Craig Jordan, V; Fan, P | 1 |
| Bjorling, DE; Keil, KP; Moses, MA; Nicholson, TM; Ricke, WA; Uchtmann, KS; Vezina, CM; Wood, RW | 1 |
| Chae, YJ; Hahn, SJ; Kim, DH; Kwon, OJ; Lee, HJ; Sung, KW | 1 |
| Ishida, A; Ishihara, Y; Itoh, K; Yamazaki, T | 1 |
| Alonso, M; Alonso, R; Cerrato, F; Fernández-Suárez, ME; Gómez-Coronado, D; Lasunción, MA; Mata, P; Pastor, O; Vázquez, C | 1 |
| DeRoo, LA; Nichols, HB; Sandler, DP; Scharf, DR | 1 |
| Carlson, EE; Couch, FJ; Goetz, MP; Ingle, JN; Kubo, M; Mushiroda, T; Nakamura, Y; Paik, S; Schaid, DJ; Vachon, CM; Wang, L; Weinshilboum, R; Wickerham, DL; Wolmark, N | 1 |
| Abreu, GR; Bissoli, NS; Caliman, IF; Dalpiaz, PL; de Melo, AF; Gouvea, SA; Lamas, AZ; Lemos, EM | 1 |
| Gail, MH | 1 |
| Gogos, A; van den Buuse, M | 1 |
| Blake, C; Lucic, A | 1 |
| Hui, Y; Kurogi, K; Liu, MC; Luo, L; Sakakibara, Y; Suiko, M; Zhang, L; Zhou, C | 1 |
| Daly, M; Holmberg, C; McCaskill-Stevens, W; Waters, EA; Whitehouse, K | 1 |
| Daly, M; Holmberg, C; McCaskill-Stevens, W; Whitehouse, K | 1 |
| Biglia, N; Bounous, VE; D'Alonzo, M; Pecchio, S; Robba, E; Sismondi, P | 1 |
| Cygankiewicz, AI; Jacenik, D; Krajewska, WM | 1 |
| Komm, BS; Pickar, JH | 1 |
| Bidinotto, LT; El-Bayoumy, K; Manni, A; Russo, J; Santucci-Pereira, J; Skibinski, CG; Thompson, HJ | 1 |
| Abramowitch, S; Knight, K; Liang, R; Moalli, PA; Nolfi, A | 1 |
| Prossnitz, ER; Zekas, E | 1 |
| Briarava, M; Mocellin, S; Nitti, D; Pilati, P | 1 |
| Eigeliene, N; Erkkola, R; Härkönen, P | 1 |
| Cuzick, J; Forster, A; Horne, R; Partridge, A; Sestak, I; Side, L; Smith, SG; Wardle, J; Wolf, MS | 1 |
| Cazzulino, AS; Denny, CA; Martinez, R; Tomm, NK | 1 |
| Aliaga, C; Calcagnotto, A; Demers, LM; DuBrock, C; El-Bayoumy, K; Hamilton, C; Hartman, TJ; Liao, J; Manni, A; McGinley, J; Prokopczyk, B; Richie, JP; Sandhu, N; Schetter, SE; Signori, C; Thompson, HJ; Trushin, N | 1 |
| Dou, J; Li, F; Li, S; Liu, J; Wei, L | 1 |
| Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P | 1 |
| Fagerlin, A; Hoerger, M; Scherer, LD | 1 |
| Burdette, JE; Davis, DA; Dean, M; Moyle-Heyrman, G; Schipma, MJ | 1 |
| Eigeliene, N; Erkkola, R; Härkönen, P; Hellmer, C; Kangas, L; Kauko, T | 1 |
| Alencar, AP; Borges, US; da Silva, BB; de Moura-Leal, AC; de Moura-Leal, H; de Sousa, GV; de Sousa, JM; Pinto, GR | 1 |
| Nazıroğlu, M; Övey, İS; Yazğan, B; Yazğan, Y | 1 |
| Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M | 1 |
| Ichimura, R; Inoue, K; Kuwata, K; Morikawa, T; Takahashi, M; Usuda, K; Watanabe, G; Yokosuka, M; Yoshida, M | 1 |
| Cuzick, J; Horne, R; Meisel, SF; Side, L; Smith, SG; Wardle, J | 1 |
| Burns, RB; Libman, H; Schonberg, MA; Tung, NM | 1 |
| Blanco-Vaca, F; Dávalos, A; Escolà-Gil, JC; Fernández-Suárez, ME; Gómez-Coronado, D; Lasunción, MA; Martínez-Botas, J; Pastor, O | 1 |
| Foygel, K; Gambhir, SS; Massoud, TF; Paulmurugan, R; Sekar, TV | 1 |
| Nazıroğlu, M; Yazğan, Y | 1 |
| Olver, IN | 1 |
| Baker, M; Blastovich, MAT; Cooper, MA; Currie, B; Elliott, AG; Han, M; Hussein, MH; Jasim, R; Li, J; Mayo, M; Morris, F; Reyes-Ortega, F; Schneider, EK; Velkov, T | 1 |
| Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Morita, M; Nakamura, M; Oike, T; Sato, Y; Tando, T; Watanabe, R | 1 |
| Marsden, J | 1 |
| Lovre, D; Mauvais-Jarvis, F; Xu, B | 1 |
| Cohen, PR | 1 |
| Brovkovych, SD; Frasor, J; Kastrati, I; Siklos, MI; Thatcher, GRJ | 1 |
| Andrade, TU; Bissoli, NS; Caliman, IF; Dalpiaz, PLM; Firmes, LB; Gouvea, SA; Lamas, AZ; Medeiros, ARS; Nascimento, AM; Oliveira, PWC; Reis, AM; Sousa, GJ | 1 |
| Crew, KD | 1 |
| Bonanni, B; Caviglia, S; Costa, A; DeCensi, A; Fontana, V; Noonan, S; Pasa, A; Peccatori, F; Smith, SG | 1 |
| Blaeser, A; Bollinger, LE; Harper, AD; Lu, P; Lu, QL; Shah, SN; Sparks, S; Wu, B | 1 |
| Gogos, A; Sbisa, A; van den Buuse, M | 1 |
| Heckman-Stoddard, B; Miller, E; Minasian, L; Pinsky, PF | 1 |
| Curtis, HJ; Goldacre, B; Walker, AJ | 1 |
| Ashraf, GM; Baez-Jurado, E; Barreto, GE; Echeverria, V; Garcia-Segura, LM; Guio-Vega, G; Hidalgo-Lanussa, O; Rincón-Benavides, MA; Sahebkar, A | 1 |
| Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W | 1 |
| Conner, EA; Pinkerton, JV | 1 |
| Anderson, C; House, M; Nichols, HB; Sandler, DP | 1 |
| Fu, R; McDonagh, M; Nelson, HD; Pappas, M; Zakher, B | 1 |
| Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Doubeni, CA; Epling, JW; Krist, AH; Kubik, M; Landefeld, CS; Mangione, CM; Owens, DK; Pbert, L; Silverstein, M; Tseng, CW; Wong, JB | 1 |
| Arevalo, M; Ball, S; Jones, C; Juarez, E; Payne, JD | 1 |
| DiNardo, D; Farkas, A; Merriam, S; Vanderberg, R | 1 |
| Bickerstaffe, A; Emery, JD; Hewabandu, N; McIntosh, JG; Minshall, J; Qama, A; Saya, S | 1 |
| Shieh, Y; Tice, JA | 1 |
| DiNome, ML; Ganz, PA; Graham, D | 1 |
| Azizian, H; Ebrahimi, MN; Karam, GA; Khaksari, M; Raji-Amirhasani, A; Sepehri, G | 1 |
| Dietze, EC; Jones, VC; Jovanovic-Talisman, T; McCune, JS; Seewaldt, VL | 1 |
| Bowles, EJA; Ehrlich, K; Farrell, D; Gao, H; Graham, AL; Jayasekera, J; Knerr, S; Leppig, K; Li, T; Luta, G; Mandelblatt, JS; O'Neill, SC; Schwartz, MD; Wernli, KJ | 1 |
| Gilman, EA; Hofstatter, EW; Mussallem, DM; Pruthi, S | 1 |
| Chan, CO; Mok, DK; Poon, CC; Wong, KY; Wong, MS; Xiao, H; Yu, W; Zhou, L | 1 |
| Aragaki, AK; Chlebowski, RT; Pan, K | 1 |
| Bender, SG; LaLonde, RL; Price, S; Till, NA; Varady, S; Yahn, R | 1 |
| Mutoh, M; Wakabayashi, K | 1 |
| Gong, S; Hong, K; Liang, JJ; Liu, TY; Qin, KM; Xie, BH; Yan, JJ; Yang, L; Yin, YP; Yu, WL; Zhou, HB | 1 |
| Hattori, Y; Hori, T; Hosokawa, Y; Kozawa, O; Matsushima-Nishiwaki, R; Tachi, J; Yamada, N | 1 |
| Azizian, H; Bashiri, H; Ebrahimi, MN; Khaksari, M; Raji-Amirhasani, A | 1 |
| Bychkovsky, B; Garber, JE; Hans, M; Katlin, F; King, TA; Knust Graichen, M; Laws, A; Pace, LE; Scheib, R | 1 |
| Adhikari, N; Bhattacharjee, M; Gupta, D; Pamnani, S; Panda, A; Rizvi, Z; Shehzad, S; Sijwali, PS; Sudhakar, R | 1 |
| Castillo, AM; Couch, FJ; Jack, CR; Kantarci, K; Kara, F; Lesnick, TG; Lohse, CM; Mielke, MM; Olson, JE; Petersen, RC; Ruddy, KJ; Tosakulwong, N | 1 |
| Laws, A; Punglia, RS | 1 |
| Babaahmadi-Rezaei, H; Mohammadtaghvaei, N; Rashidi, M; Zarezade, V | 1 |
| Aeilts, A; Bordeleau, L; Cullinane, CA; Eisen, A; Eng, C; Foulkes, WD; Fruscio, R; Gronwald, J; Huzarski, T; Karlan, B; Kotsopoulos, J; Lubinski, J; Metcalfe, K; Narod, SA; Neuhausen, SL; Olopade, O; Pal, T; Randall Armel, S; Singer, CF; Sun, P; Tung, N | 1 |
| Allegretti, M; Cesta, CM; Locati, M; Pepe, G; Sfogliarini, C; Vegeto, E | 1 |
221 review(s) available for raloxifene hydrochloride and tamoxifen
| Article | Year |
|---|---|
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Half-Life; Humans; Mammary Neoplasms, Experimental; Models, Biological; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Thiophenes | 1983 |
Alternate antiestrogens and approaches to the prevention of breast cancer.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Estrogen Antagonists; Female; Humans; Liver Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Tamoxifen; Toremifene | 1995 |
[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
Topics: Animals; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1995 |
Clinical potential of new antiestrogens.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene | 1997 |
Skeletal effects of estrogen analogs.
Topics: Bone and Bones; Estradiol Congeners; Estrogen Antagonists; Estrogens; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1997 |
Gonadal hormone substitutes: effects on the cardiovascular system.
Topics: Animals; Coronary Disease; Coronary Vessels; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1997 |
Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Topics: Bone Resorption; Cholesterol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Uterus | 1998 |
Status of antiestrogen breast cancer prevention trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Italy; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; United Kingdom; United States | 1998 |
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor alpha; Uterine Neoplasms | 1998 |
The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Approval; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Patient Selection; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States; United States Food and Drug Administration | 1999 |
Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene.
Topics: Animals; Breast Neoplasms; Crystallization; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Stimulation, Chemical; Tamoxifen | 1998 |
Current controversies in breast cancer management.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Patient Selection; Piperidines; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Tamoxifen | 1999 |
Prevention of breast cancer in high-risk women.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Incidence; Louisiana; Middle Aged; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 1999 |
Estrogen receptor as a target for the prevention of breast cancer.
Topics: Animals; Breast Neoplasms; Estrogen Antagonists; Humans; Meta-Analysis as Topic; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen | 1999 |
Development of a new prevention maintenance therapy for postmenopausal women.
Topics: Adult; Aged; Animals; Breast Neoplasms; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Rats; Tamoxifen | 1999 |
Selective estrogen receptor modulators: a look ahead.
Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Toremifene | 1999 |
Tamoxifen, raloxifene, and the prevention of breast cancer.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Tamoxifen | 1999 |
Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women.
Topics: Aged; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Middle Aged; Osteoporosis, Postmenopausal; Phytoestrogens; Piperidines; Plant Preparations; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1999 |
[Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Effect of SERMs on the uterus and menopausal symptoms.
Topics: Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Effect of SERMs on breast tissue.
Topics: Animals; Breast; Breast Neoplasms; Estrogens; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Tolerability profile of SERMs.
Topics: Animals; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis | 1999 |
Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Modulators; Europe; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United States | 1999 |
Modern antioestrogens and the coming revolution in women's health care.
Topics: Bone and Bones; Breast Neoplasms; Clomiphene; Estradiol; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Genital Diseases, Female; Humans; Isoflavones; Osteoporosis; Phytoestrogens; Plant Preparations; Plants; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 1999 |
Preventing heart disease and cancer. What randomized, primary-prevention studies show.
Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Coronary Disease; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selenium; Tamoxifen; Vitamin E | 1999 |
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Topics: Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cataract; Endometrial Neoplasms; Estrogen Antagonists; Expert Testimony; Female; Humans; Incidence; Menopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen | 1999 |
Selective estrogen receptor modulators and postmenopausal health.
Topics: Breast Neoplasms; Chemoprevention; Dementia; Female; Fractures, Bone; Heart Diseases; Humans; Lipoproteins; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 2000 |
[Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
Topics: Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Chemoprevention of breast cancer in the older patient.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Retinoids; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Selective oestrogen receptor modulation: molecular pharmacology for the millennium.
Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Hormonal approaches to the chemoprevention of endocrine-dependent tumors.
Topics: Aromatase Inhibitors; Chemoprevention; Endocrine Gland Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Tamoxifen | 1999 |
Prevention of breast cancer.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Biological Products; Breast Neoplasms; Breast Neoplasms, Male; Carotenoids; Cathepsin D; Cell Adhesion Molecules; Cell Cycle; Clinical Trials, Phase III as Topic; Drug Screening Assays, Antitumor; Estrogens, Non-Steroidal; Female; Fenretinide; Genetic Predisposition to Disease; Hormone Antagonists; Humans; Isoflavones; Male; Mammary Neoplasms, Experimental; Mastectomy; Mice; Middle Aged; Neovascularization, Pathologic; Ovariectomy; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Rats; Retinoids; Risk Assessment; Risk Factors; Selenium; Tamoxifen; Terpenes | 2000 |
[Breast cancer: assessment of individual risk and possibilities for prevention].
Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Genetic Carrier Screening; Genetic Predisposition to Disease; Humans; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen | 2000 |
Drugs for the gynecologist to prescribe in the prevention of breast cancer: current status and future trends.
Topics: Breast Neoplasms; Drug Approval; Estrogen Antagonists; Female; Gynecology; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; United States; United States Food and Drug Administration | 2000 |
Targeted antiestrogens for the prevention of breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Forecasting; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1999 |
[Chemopreventive effect of tamoxifen on familial breast cancer].
Topics: Animals; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplastic Syndromes, Hereditary; Raloxifene Hydrochloride; Rats; Seaweed; Tamoxifen; Tea | 2000 |
Selective estrogen receptor modulators in reproductive medicine and biology.
Topics: Estradiol; Estrogen Replacement Therapy; Fulvestrant; Genistein; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Reducing the risk of breast cancer.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Environment; Estrogen Antagonists; Female; Humans; Life Style; Mastectomy; Ovariectomy; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2000 |
Safety and efficacy of antiestrogens for prevention of breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2000 |
Prevention and treatment of osteoporosis in women with breast cancer.
Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Chemoprevention of breast cancer.
Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Bone and Bones; Breast Diseases; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis, Postmenopausal; Pilot Projects; Precancerous Conditions; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproductive History; Risk Factors; Safety; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Chemoprevention of breast cancer.
Topics: Adult; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Mastectomy; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2000 |
[Breast cancer chemoprevention (tamoxifen, raloxifene, and others)].
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Retinoids; Seaweed; Selective Estrogen Receptor Modulators; Tamoxifen; Tea | 2000 |
The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception.
Topics: Contraceptive Agents, Female; Estrogen Antagonists; Female; Humans; Neovascularization, Physiologic; Progestins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Hemorrhage | 2000 |
In pursuit of the prevention of breast cancer.
Topics: Age Factors; Animals; Anticarcinogenic Agents; Breast Neoplasms; Cohort Studies; Confounding Factors, Epidemiologic; Contraceptives, Oral, Hormonal; Disease Models, Animal; Emigration and Immigration; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Italy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Twin Studies as Topic; United Kingdom | 2000 |
Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Breast cancer chemoprevention.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Breast cancer prevention trials.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Tamoxifen | 2000 |
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.
Topics: Aged; Breast Neoplasms; Cholesterol; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Incidence; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Progress in the prevention of breast cancer: concept to reality.
Topics: Bone Density; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Breast cancer genetics. Implications of clinical practice.
Topics: Age of Onset; Anticarcinogenic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Case Management; Cyclin D1; DNA Mutational Analysis; Estrogen Antagonists; Female; Gene Frequency; Genes, BRCA1; Genes, erbB-2; Genetic Counseling; Genetic Testing; Humans; Male; Mammography; Mastectomy; Neoplasm Proteins; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Oncogenes; Ovarian Neoplasms; Ovariectomy; Phenotype; Raloxifene Hydrochloride; Retrospective Studies; Risk; Tamoxifen; Transcription Factors | 2000 |
Breast cancer chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Hyperlipidemias; Hysterectomy; Mammary Neoplasms, Experimental; Menopause; Mice; Mice, Nude; Middle Aged; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Tamoxifen; United States | 2000 |
Chemoprevention of breast cancer.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Contraindications; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Incidence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United States; United States Food and Drug Administration | 2001 |
Chemoprevention of breast cancer.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
[Prevention of breast cancer--what are the latest developments?].
Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Replacement Therapy; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2001 |
Future possibilities in the prevention of breast cancer: breast cancer prevention trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Forecasting; Hormone Replacement Therapy; Humans; Incidence; Menopause; Meta-Analysis as Topic; Middle Aged; Neoplasm Proteins; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome | 2000 |
Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aromatase; Breast Neoplasms; Case-Control Studies; Estradiol Dehydrogenases; Estrogen Receptor alpha; Estrogens; Ethnicity; Female; Forecasting; Genetic Predisposition to Disease; Genetic Testing; Humans; Middle Aged; Models, Genetic; Ovary; Polymorphism, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Reproductive History; Risk Factors; Selective Estrogen Receptor Modulators; Steroid 17-alpha-Hydroxylase; Tamoxifen | 2000 |
Breast cancer chemoprevention: beyond tamoxifen.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Novel agents to modulate oestrogen action.
Topics: Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
The prevention of breast cancer: an overview.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Breast Neoplasms; Cyclooxygenase Inhibitors; Estrogen Receptor Modulators; Evidence-Based Medicine; Female; Humans; Life Style; Mastectomy; Primary Prevention; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2001 |
SERMs and cardiovascular disease in women. How do these agents affect risk?
Topics: Blood Coagulation Factors; Cardiovascular Diseases; Estrogens, Non-Steroidal; Female; Glycine max; Humans; Isoflavones; Lipid Metabolism; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
[An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)].
Topics: Adult; Aged; Animals; Bone and Bones; Brain; Breast; Breast Neoplasms; Cardiovascular System; Endometrial Neoplasms; Female; Haplorhini; Hormone Replacement Therapy; Humans; Menopause; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus; Vagina | 2001 |
[SERM--selective estrogen receptor modulators].
Topics: Aged; Bone Marrow; Breast; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Estrogen Antagonists; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Breast cancer chemoprevention: current status and future directions.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Incidence; Italy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United Kingdom; United States | 2001 |
Tamoxifen to raloxifene and beyond.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Topics: Adult; Breast Neoplasms; Canada; Female; Humans; Middle Aged; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Familiar drugs may prevent cancer.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticarcinogenic Agents; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Female; Folic Acid; Humans; Male; Neoplasms; Pyrazoles; Raloxifene Hydrochloride; Sulfonamides; Tamoxifen; Vitamin A | 2001 |
Tamoxifen, screening and new oestrogen receptor modulators.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Dose-Response Relationship, Drug; Endometrial Neoplasms; Endosonography; Female; Humans; Hysteroscopy; Mass Screening; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sensitivity and Specificity; Tamoxifen | 2001 |
Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Design; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2001 |
Risk-reduction mastectomy: clinical issues and research needs.
Topics: Anticarcinogenic Agents; Attitude to Health; Breast Neoplasms; Decision Making; Estrogen Receptor Modulators; Female; Genes, BRCA1; Genes, Tumor Suppressor; Heterozygote; Humans; Incidence; Mammography; Mastectomy; Mutation; Ovariectomy; Population Surveillance; Raloxifene Hydrochloride; Risk; Tamoxifen | 2001 |
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Topics: Adult; Aged; Bone and Bones; Breast; Breast Neoplasms; Cardiovascular System; Cinnamates; Clinical Trials as Topic; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Heart; Hot Flashes; Humans; Middle Aged; Models, Biological; Organ Specificity; Osteoporosis; Postmenopause; Premenopause; Prospective Studies; Protein Structure, Tertiary; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thrombophilia; Transcription, Genetic | 2001 |
Breast cancer prevention.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Life Style; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Breast cancer chemoprevention: current clinical practice and future direction.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2001 |
Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review.
Topics: Animals; Disease Models, Animal; Estrogen Replacement Therapy; Female; Humans; Leiomyoma; Norpregnenes; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2001 |
A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials.
Topics: Adult; Age Distribution; Aged; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors.
Topics: Cardiovascular Diseases; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Menopause; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Preventing and treating osteoporosis: strategies at the millennium.
Topics: Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
The effect of SERMs on the endometrium.
Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Humans; Neoplasm Invasiveness; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Topics: Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Breast cancer risk reduction: strategies for women at increased risk.
Topics: Breast Neoplasms; Female; Humans; Mastectomy; Ovariectomy; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Breast cancer prevention: present and future.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2001 |
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cinnamates; Drug Design; Forecasting; Humans; Molecular Biology; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Toremifene; Treatment Outcome | 2002 |
Selective estrogen receptor modulators.
Topics: Aged; Animals; Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 1998 |
Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.
Topics: Animals; Benzopyrans; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Naphthalenes; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 1999 |
Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Fenretinide; Humans; Incidence; Insulin-Like Growth Factor I; Multicenter Studies as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Chemoprevention of breast cancer: implications for postmenopausal women.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Estrogens; Female; Gene Expression Regulation, Neoplastic; Hormone Replacement Therapy; Humans; Postmenopause; Precancerous Conditions; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Identifying and counseling women at increased risk for breast cancer.
Topics: Adult; Breast Neoplasms; Clinical Trials as Topic; Counseling; Female; Humans; Life Style; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Tamoxifen, raloxifene and the prevention of breast cancer.
Topics: Adult; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Coronary Disease; Drug Design; Endometrial Neoplasms; Estrogens; Female; Humans; Incidence; Mammary Neoplasms, Experimental; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2002 |
The search for the ideal SERM.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Cognition; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Evidence-Based Medicine; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2002 |
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Enzyme Inhibitors; Estrogen Antagonists; Evidence-Based Medicine; Expert Testimony; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen | 2002 |
[Selective estrogen receptor modulators (SERMs) in the practice].
Topics: Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2002 |
Selective estrogen receptor modulators: tissue actions and potential for CNS protection.
Topics: Animals; Breast Neoplasms; Cardiovascular System; Central Nervous System; Cognition; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy; Humans; Hypothalamo-Hypophyseal System; Male; Neuroprotective Agents; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Neurotransmitter; Structure-Activity Relationship; Tamoxifen; Thiophenes; Uterus | 2002 |
[Specific estrogen receptor modulators (SERMs)].
Topics: Adult; Antineoplastic Agents, Hormonal; Bone and Bones; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Endometrium; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Lipid Metabolism; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Polyunsaturated Alkamides; Postmenopause; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2002 |
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
Chemoprevention of breast cancer: current and future prospects.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Forecasting; Humans; Raloxifene Hydrochloride; Tamoxifen | 2002 |
Overview of the main outcomes in breast-cancer prevention trials.
Topics: Breast Neoplasms; Cause of Death; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Incidence; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2003 |
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
Topics: Bone and Bones; Breast; Breast Neoplasms; Central Nervous System; Coronary Disease; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Urogenital System | 2003 |
Application of breast cancer risk prediction models in clinical practice.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Models, Biological; Predictive Value of Tests; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen | 2003 |
Anti-oestrogenic chemoprevention of breast cancer-the need to progress.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Pilot Projects; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Topics: Animals; Antineoplastic Agents; Drug Resistance; Endometrial Neoplasms; Estradiol Congeners; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Humans; Models, Molecular; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Steroids; Structure-Activity Relationship; Tamoxifen | 2003 |
Chemoprevention of breast cancer: recommendations and rationale.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Evidence-Based Medicine; Female; Humans; Practice Guidelines as Topic; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; Venous Thrombosis | 2003 |
Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
[Breakthrough in breast cancer chemoprevention].
Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Fenretinide; Genes, BRCA1; Genes, BRCA2; Humans; Insulin-Like Growth Factor I; Menopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Time Factors | 2003 |
[SERMs and uterus].
Topics: Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms; Uterus | 2003 |
Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Long-Term Care; Middle Aged; Neoplasm Staging; Postmenopause; Premenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen; Treatment Outcome | 2003 |
New approaches to the endocrine prevention and treatment of breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2003 |
Antiestrogens: the past and the future.
Topics: Animals; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States | 2002 |
The prevention of breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Double-Blind Method; Estrogen Antagonists; Female; Forecasting; Genes, BRCA1; Genes, BRCA2; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retinoids; Tamoxifen | 2003 |
Selective estrogen-receptor modulators.
Topics: Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
Prevention of breast cancer using SERMs and aromatase inhibitors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Risk; Sarcoma; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2003 |
Pharmacological prevention of breast cancer: quo vadis?
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Fenretinide; Humans; Raloxifene Hydrochloride; Tamoxifen | 2003 |
Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
Topics: Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
[Raloxifene and breast: from the SERMs concept to its place in clinical practice].
Topics: Aged; Animals; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Mice; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen | 2004 |
Progress in chemoprevention of breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Fenretinide; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2004 |
The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Selective estrogen receptor modulation: concept and consequences in cancer.
Topics: Apoptosis; Breast Neoplasms; Dimerization; Drug Resistance; Endometrial Neoplasms; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Osteoporosis; Protein Binding; Protein Conformation; Protein Interaction Mapping; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; Tamoxifen | 2004 |
Therapeutic targeting in the estrogen receptor hormonal pathway.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Humans; Ligands; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen | 2004 |
Endocrine therapy for early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Postmenopause; Prognosis; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2004 |
[Hormone therapy for uterine corpus cancer--introduction].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxyprogesterones; Leuprolide; Medroxyprogesterone Acetate; Raloxifene Hydrochloride; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2004 |
[Additional effect of SERM: mammary gland].
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, LDL; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2004 |
[Effects of raloxifene on other organs without bone: uterus].
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Myometrium; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Diseases | 2004 |
Prevention of hormone-related cancers: breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
Topics: Aging; Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Estrogen Replacement Therapy; Female; Humans; Menopause; Middle Aged; Norpregnenes; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Selective estrogen-receptor modulators for primary prevention of breast cancer.
Topics: Aged; Breast Neoplasms; Female; Humans; Postmenopause; Premenopause; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
[Selective estrogen receptor modulators].
Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2004 |
Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Topics: Breast Neoplasms; Female; Humans; Piperidines; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2005 |
Effects of oestrogen receptor-active compounds on lipid metabolism.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Female; Humans; Lipid Metabolism; Male; Norpregnenes; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
[Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 2006 |
The prevention, detection, and management of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Mammaplasty; Mammography; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Sentinel Lymph Node Biopsy; Surgical Flaps; Tamoxifen; Time Factors; Trastuzumab; Ultrasonography, Mammary | 2006 |
[SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
Topics: Breast Neoplasms; Female; Fractures, Bone; France; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
The science of selective estrogen receptor modulators: concept to clinical practice.
Topics: Breast Neoplasms; Female; Humans; Models, Biological; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2006 |
[SERM].
Topics: Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Modifiers of risk of hereditary breast cancer.
Topics: Abortion, Therapeutic; Breast Feeding; Breast Neoplasms; Contraceptives, Oral; Female; Genes, BRCA1; Genes, BRCA2; Genetic Carrier Screening; Humans; Ovariectomy; Pregnancy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
An update on breast cancer prevention trials.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
[Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
Topics: Cardiovascular Diseases; Estrogen Antagonists; Estrogens; Female; Hormone Replacement Therapy; Humans; Longitudinal Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Selecting targets for cancer prevention: where do we go from here?
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Humans; Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2006 |
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Prevention of breast cancer: current state of the science and future opportunities.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Evaluation, Preclinical; Drug Therapy, Combination; Estrogen Receptor Modulators; Estrogens; Female; Forecasting; Humans; Leuprolide; Mammary Neoplasms, Experimental; Mice; Middle Aged; Ovariectomy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Rats; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Chemoprevention of breast cancer with selective oestrogen-receptor modulators.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Endometrial Neoplasms; Female; Humans; Models, Biological; Models, Chemical; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
The current status of breast cancer chemoprevention: a star is born.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Risk Assessment; Tamoxifen | 2007 |
The cardiovascular effects of selective estrogen receptor modulators.
Topics: Cardiovascular System; Estradiol; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2006 |
SERMs: meeting the promise of multifunctional medicines.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Evidence-Based Medicine; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2007 |
Primary prevention of breast cancer: new approaches.
Topics: Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Female; Humans; Life Style; Mammography; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Finasteride; Humans; Male; Primary Prevention; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
SERMs for the treatment and prevention of breast cancer.
Topics: Breast Neoplasms; Female; Humans; Postmenopause; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Moving forward with breast cancer prevention.
Topics: Aged; Breast Neoplasms; Female; Humans; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2007 |
Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Topics: Breast Neoplasms; Drug Design; Estrogen Receptor alpha; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stilbenes; Structure-Activity Relationship; Tamoxifen; Thiophenes; Toremifene | 2007 |
Raloxifene, tamoxifen and vascular tone.
Topics: Animals; Atherosclerosis; Blood Vessels; Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Circulation; Collateral Circulation; Coronary Circulation; Endothelium, Vascular; Estrogen Replacement Therapy; Female; Humans; Nitric Oxide; Pulmonary Circulation; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vasodilation | 2007 |
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Drug Delivery Systems; Gene Expression Profiling; Genes, BRCA1; Genes, BRCA2; Genetic Carrier Screening; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Prognosis; Raloxifene Hydrochloride; Tamoxifen | 2008 |
Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2007 |
[Prevention of hereditary breast cancer].
Topics: Apoptosis Regulatory Proteins; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Heterozygote; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy, Simple; Mutation; Plastic Surgery Procedures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
[Current perspective of chemoprevention in breast cancer].
Topics: Apoptosis Regulatory Proteins; Aromatase Inhibitors; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Female; Humans; Meta-Analysis as Topic; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Effects of hormone treatment on hemostasis variables.
Topics: Administration, Oral; Administration, Topical; Dose-Response Relationship, Drug; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Ethinyl Estradiol; Female; Hemostasis; Humans; Inflammation; Norpregnenes; Progestins; Raloxifene Hydrochloride; Tamoxifen; Venous Thromboembolism | 2007 |
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cognition; Female; Gonadotropin-Releasing Hormone; Humans; Neuropsychological Tests; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Topics: Breast Neoplasms; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Tamoxifen: catalyst for the change to targeted therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Female; History, 20th Century; History, 21st Century; Humans; Osteoporosis; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Breast cancer risk management.
Topics: Antineoplastic Agents; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Humans; Primary Health Care; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; United States; Women's Health | 2007 |
Chemoprevention of breast cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Carotenoids; Chemoprevention; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phytoestrogens; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Gene expression profiles in breast cancer to identify estrogen receptor target genes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2008 |
Preventing breast cancer in high-risk women, 2008.
Topics: Algorithms; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Prevention of breast cancer using SERMs.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
Topics: Estrogen Replacement Therapy; Estrogens; Female; Humans; Norpregnenes; Ovarian Neoplasms; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms | 2008 |
The endocrine prevention of breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Chemoprevention of breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Modulators; Female; Humans; Mass Screening; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Topics: Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
The use of tamoxifen and raloxifene for the prevention of breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2009 |
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Case-Control Studies; Confidence Intervals; Confounding Factors, Epidemiologic; Estrogen Receptor Modulators; Female; Gonadal Steroid Hormones; Humans; Life Style; Middle Aged; Models, Statistical; Odds Ratio; Postmenopause; Predictive Value of Tests; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tamoxifen | 2009 |
[Breast cancer chemoprevention. Rational, trials results and future].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Family Health; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles | 2009 |
The rationale and potential of cancer chemoprevention with special emphasis on breast cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Raloxifene Hydrochloride; Retinoids; Tamoxifen | 2009 |
Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.
Topics: Cardiovascular Diseases; Female; Humans; Indoles; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2009 |
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health | 2009 |
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Topics: Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Norpregnenes; Raloxifene Hydrochloride; Stroke; Tamoxifen; Thromboembolism | 2009 |
In the clinic. Breast cancer screening and prevention.
Topics: Age Factors; Breast Neoplasms; Cost-Benefit Analysis; Estrogen Antagonists; Female; Humans; Mammography; Mass Screening; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Time Factors | 2010 |
Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women.
Topics: Estradiol; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Meta-Analysis as Topic; Middle Aged; Pelvic Organ Prolapse; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Ductal carcinoma in situ: risk factors and impact of screening.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemoprevention; Female; Hormone Replacement Therapy; Humans; Incidence; Mammography; Mass Screening; Middle Aged; Multicenter Studies as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Young Adult | 2010 |
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperplasia; Incidence; Multicenter Studies as Topic; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2010 |
Selective estrogen receptor modulators as brain therapeutic agents.
Topics: Animals; Apoptosis; Brain; Brain Diseases; Brain Injuries; Encephalitis; Humans; Mood Disorders; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Contraindications; Drug Therapy, Combination; Female; Humans; Italy; Mass Screening; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Modulators of androgen and estrogen receptor activity.
Topics: Androgen Receptor Antagonists; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Osteoporosis; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
Selective oestrogen receptor modulators decrease the inflammatory response of glial cells.
Topics: Animals; Anti-Inflammatory Agents; Encephalitis; Neuroglia; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen | 2012 |
Chemoprevention for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2012 |
Breast cancer chemoprevention.
Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen | 2012 |
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Fractures, Bone; Humans; Medication Adherence; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; Thromboembolism; Treatment Outcome | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Topics: Atrophy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Pelvic Organ Prolapse; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Vagina; Vaginal Diseases; Vulva; Vulvar Diseases | 2014 |
Use of SERMs for treatment in postmenopausal women.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Effect of preventive hormonal therapy on breast density: a systematic qualitative review.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Humans; Raloxifene Hydrochloride; Tamoxifen | 2014 |
Chemoprevention or mastectomy for women at high risk of developing breast cancer.
Topics: Age Factors; Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Female; Humans; Mastectomy; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
[GPER receptor - the new player in estrogen signaling].
Topics: Animals; Autocrine Communication; Breast Neoplasms; Connective Tissue Growth Factor; Dual Specificity Phosphatase 1; Estradiol; Female; Fulvestrant; Gene Expression Regulation; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Tamoxifen; Transcriptional Activation | 2015 |
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2015 |
Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Estrogen Receptor Modulators; Fatty Acids, Omega-3; Female; Humans; Proteomics; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2015 |
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Norpregnenes; Piperidines; Postmenopause; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2016 |
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
Topics: Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2016 |
The selective estrogen receptor modulators in breast cancer prevention.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2016 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles | 2016 |
Prevention of breast cancer.
Topics: Alcohol Drinking; Australia; Breast Neoplasms; Female; Genes, BRCA1; Genetic Testing; Hormone Replacement Therapy; Humans; Life Style; Mammography; Mastectomy; Obesity; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Tobacco Use | 2016 |
Breast cancer chemoprevention: A service in need of menopause specialist support.
Topics: Breast Neoplasms; Counseling; Female; Humans; Menopause; Patient Education as Topic; Physician's Role; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; United Kingdom | 2017 |
The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.
Topics: Aging; Animals; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Indoles; Insulin Resistance; Models, Biological; Obesity; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2017 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2018 |
Molecular mechanisms involved in the protective actions of Selective Estrogen Receptor Modulators in brain cells.
Topics: Animals; Astrocytes; Brain Diseases; Humans; Neuroprotective Agents; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2019 |
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators.
Topics: Adult; Aged; Atrophy; Breast Neoplasms; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina | 2019 |
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adult; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mutation; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2019 |
Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians.
Topics: Breast Neoplasms; Chemoprevention; Female; Guidelines as Topic; Health Knowledge, Attitudes, Practice; Humans; Physicians, Primary Care; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2019 |
Medications for Primary Prevention of Breast Cancer.
Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms; Venous Thromboembolism | 2020 |
Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer.
Topics: Breast Neoplasms; Female; Humans; Metformin; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Curriculum; Decision Making, Shared; Education, Medical, Continuing; Estrogen Antagonists; Female; Health Personnel; Humans; Male; Middle Aged; Preventive Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2021 |
Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.
Topics: Animals; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Students; Tamoxifen | 2021 |
Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.
Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Raloxifene Hydrochloride; Secondary Prevention; Tamoxifen | 2023 |
31 trial(s) available for raloxifene hydrochloride and tamoxifen
| Article | Year |
|---|---|
Antiestrogenic properties of raloxifene.
Topics: Adult; Analysis of Variance; Drug Interactions; Estradiol; Estrogen Antagonists; Ethinyl Estradiol; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Humans; Luteinizing Hormone; Male; Middle Aged; Piperidines; Pituitary Hormones, Anterior; Prolactin; Raloxifene Hydrochloride; Sex Hormone-Binding Globulin; Tamoxifen; Testosterone; Transcortin | 1995 |
Drugs can reduce the incidence of breast cancer: now what?
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Premenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 1999 |
The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1).
Topics: Breast Neoplasms; Carcinoma in Situ; Drug Resistance; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States | 2001 |
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Eligibility Determination; Female; Hawaii; Humans; Patient Participation; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 2002 |
Overview of the main outcomes in breast-cancer prevention trials.
Topics: Breast Neoplasms; Cause of Death; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Incidence; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2003 |
Short-term urogenital effects of raloxifene, tamoxifen, and estrogen.
Topics: Aged; Atrophy; Double-Blind Method; Estradiol; Estrogens; Estrogens, Conjugated (USP); Estrone; Female; Humans; Menopause; Middle Aged; Placebos; Raloxifene Hydrochloride; Tamoxifen; Urethra; Uterine Prolapse; Vagina | 2003 |
Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.
Topics: Double-Blind Method; Drug Administration Schedule; Female; Follicle Stimulating Hormone; Hot Flashes; Humans; Lipids; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin; Tamoxifen; Treatment Outcome; Uterus; Vagina | 2005 |
Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
Topics: Biomarkers; Blood Coagulation Factor Inhibitors; Blood Coagulation Factors; Estrogens; Female; Fibrinolysis; Hemostasis; Hormone Replacement Therapy; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombophilia | 2005 |
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms | 2006 |
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Topics: Adult; Aged; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women.
Topics: Biomarkers; Bone Remodeling; Collagen; Double-Blind Method; Female; Finland; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 2006 |
The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.
Topics: Adult; Dose-Response Relationship, Drug; Follicle Stimulating Hormone; Humans; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Male; Middle Aged; Oligospermia; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sperm Count; Sperm Motility; Tamoxifen; Testis; Testosterone; Toremifene | 2009 |
Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.
Topics: Aged; Breast Neoplasms; Cognition; Female; Humans; Middle Aged; Neuropsychological Tests; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition.
Topics: Aged; Breast Neoplasms; Cognition; Estrogens, Conjugated (USP); Female; Humans; Middle Aged; Neuropsychological Tests; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus | 2010 |
Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men.
Topics: Aged; Androgens; Arginine; Cross-Over Studies; Follicle Stimulating Hormone; Growth Hormone; Humans; Insulin-Like Growth Factor I; Luteinizing Hormone; Male; Middle Aged; Raloxifene Hydrochloride; Reference Values; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin; Tamoxifen; Testosterone | 2010 |
Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study.
Topics: Adolescent; Adult; Antineoplastic Agents; Breast; Double-Blind Method; Female; Fibroadenoma; Humans; Immunohistochemistry; Placebos; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Decision Making; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Patient Education as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 2011 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles | 2012 |
Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifen.
Topics: Calcium; Collagen Type I; Estrogens; Female; Humans; Interleukin-6; Kidney; Middle Aged; Parathyroid Hormone; Peptides; Prospective Studies; Raloxifene Hydrochloride; Tamoxifen | 2012 |
Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.
Topics: Aged; Aged, 80 and over; Arginine; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Liver; Luteinizing Hormone; Male; Middle Aged; Neurosecretion; Pituitary Gland, Anterior; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sex Characteristics; Sex Hormone-Binding Globulin; Tamoxifen; Testosterone | 2012 |
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
Topics: Antineoplastic Agents; Black or African American; Breast Neoplasms; Chemoprevention; Community-Based Participatory Research; Double-Blind Method; Female; Hispanic or Latino; Humans; Patient Education as Topic; Patient Selection; Racial Groups; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; White People | 2013 |
Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer.
Topics: Aged; Breast Neoplasms; Conflict, Psychological; Decision Support Techniques; Female; Humans; Internet; Michigan; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Treatment Outcome | 2013 |
Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Ethinyl Estradiol; Female; Humans; Menopause; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina; Vaginal Diseases; Vulva | 2013 |
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.
Topics: Adolescent; Adult; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Placebos; Premenopause; Raloxifene Hydrochloride; Tamoxifen | 2013 |
Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
Topics: Adult; Aged; Breast Neoplasms; Chemoprevention; Decision Making; Decision Support Techniques; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Informed Consent; Internet; Middle Aged; Premedication; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2013 |
Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study.
Topics: Aged; Anticarcinogenic Agents; Breast Neoplasms; Cognition; Cognition Disorders; Female; Humans; Logistic Models; Medication Adherence; Middle Aged; Neuropsychological Tests; Postmenopause; Raloxifene Hydrochloride; Risk; Tamoxifen | 2014 |
Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial.
Topics: Adult; Aged; Body Mass Index; Breast; Breast Density; Breast Neoplasms; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Eicosapentaenoic Acid; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Mammography; Middle Aged; Obesity; Raloxifene Hydrochloride; Tamoxifen | 2016 |
Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Density; Breast Neoplasms; Communication; Female; Humans; Internet-Based Intervention; Magnetic Resonance Imaging; Mammography; Middle Aged; Odds Ratio; Patient Reported Outcome Measures; Psychological Distress; Raloxifene Hydrochloride; Risk; Self Report; Tamoxifen; Washington | 2021 |
406 other study(ies) available for raloxifene hydrochloride and tamoxifen
| Article | Year |
|---|---|
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Structure-Activity Relationship; Uterus | 1984 |
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Topics: Animals; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tumor Cells, Cultured | 1997 |
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Topics: Administration, Oral; Animals; Binding Sites; Biological Availability; Cell Division; Crystallography, X-Ray; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; HeLa Cells; Humans; Isoquinolines; Ligands; Models, Molecular; Radioligand Assay; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Chalcones; Flavonoids; Humans; Structure-Activity Relationship | 2017 |
Effects of antiestrogens on adult and neonatal mouse reproductive organs.
Topics: Animals; Animals, Newborn; Body Weight; Clomiphene; Estrogen Antagonists; Female; Genitalia, Female; Genitalia, Male; Male; Mice; Mice, Inbred C57BL; Nafoxidine; Organ Size; Ovariectomy; Ovary; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Trifluoperazine; Uterus; Vagina | 1992 |
Tamoxifen-stimulated growth of human endometrial carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Clomiphene; Enclomiphene; Endometrium; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Mice, Inbred BALB C; Nafoxidine; Neoplasm Transplantation; Piperidines; Polyunsaturated Alkamides; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Uterine Neoplasms | 1991 |
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.
Topics: Androgens; Androstane-3,17-diol; Binding, Competitive; Cell Cycle; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Antagonism; Estradiol; Estrogen Antagonists; Estrone; Flow Cytometry; Flutamide; Humans; In Vitro Techniques; Male; Metribolone; Piperidines; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen; Testosterone; Time Factors; Tumor Cells, Cultured | 1991 |
Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cattle; Cell Division; Contact Inhibition; Culture Media; Estradiol; Estrogens; Humans; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1991 |
The stimulation of uterine complement component C3 gene expression by antiestrogens.
Topics: Animals; Complement C3; Drug Interactions; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Gene Expression Regulation; Kinetics; Nucleic Acid Hybridization; Piperidines; Progesterone; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; RNA, Messenger; Tamoxifen; Thiophenes; Uterus | 1990 |
Antiestrogen and antiandrogen administration reduce bone mass in the rat.
Topics: Androgen Antagonists; Animals; Bone Density; Bone Diseases, Metabolic; Cyproterone; Cyproterone Acetate; Estrogen Antagonists; Female; Hexestrol; Male; Orchiectomy; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Tamoxifen; Testosterone | 1989 |
Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Topics: Binding, Competitive; Breast Neoplasms; Cell Division; Dexamethasone; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Humans; Piperidines; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1989 |
Estrogen dependence of luteinizing hormone receptor expression in cultured rat granulosa cells. Inhibition of granulosa cell development by the antiestrogens tamoxifen and keoxifene.
Topics: Animals; Cells, Cultured; Cyclic AMP; Estradiol; Estrogen Antagonists; Estrogens; Female; Granulosa Cells; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Cell Surface; Receptors, LH; Tamoxifen | 1985 |
Antagonism of sexual behavior in female rats by ventromedial hypothalamic implants of antiestrogen.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Hypothalamus, Middle; Piperidines; Posture; Progesterone; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Sexual Behavior, Animal; Tamoxifen | 1987 |
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Topics: Animals; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasms, Hormone-Dependent; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Time Factors; Uterus | 1987 |
Effects of anti-estrogens on bone in castrated and intact female rats.
Topics: Animals; Body Weight; Bone and Bones; Estradiol; Estrogen Antagonists; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Tamoxifen | 1987 |
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Topics: Animals; Breast Neoplasms; Castration; Cell Division; Cell Line; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Piperidines; Progesterone; Raloxifene Hydrochloride; Tamoxifen | 1985 |
Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Castration; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Female; Luteinizing Hormone; Mammary Neoplasms, Experimental; Piperidines; Prolactin; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Tamoxifen | 1983 |
Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line; Estrogen Antagonists; Female; Humans; Mammary Neoplasms, Experimental; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Thiophenes; Uterus | 1984 |
Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY 156758 and tamoxifen.
Topics: Animals; Drug Antagonism; Estradiol; Female; Lactalbumin; Lactation; Macaca mulatta; Macaca nemestrina; Mammary Glands, Animal; Organ Culture Techniques; Piperidines; Pregnancy; Progesterone; Prolactin; Raloxifene Hydrochloride; Tamoxifen | 1983 |
Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Organ Size; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Tamoxifen; Thiophenes; Uterus | 1983 |
Antagonism of estrogen action with a new benzothiophene derived antiestrogen.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Hypertrophy; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Uterus | 1983 |
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
Topics: Animals; Bone Density; Breast Neoplasms; Cell Division; Cholesterol; Ethinyl Estradiol; Female; Humans; Middle Aged; Organ Size; Organ Specificity; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterus | 1995 |
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.
Topics: Animals; Cell Line; Chlorocebus aethiops; DNA; Estradiol; Estrogen Antagonists; Gene Expression Regulation; Kidney; Molecular Structure; Piperidines; Polyunsaturated Alkamides; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Proteins; Structure-Activity Relationship; Tamoxifen; Transfection | 1995 |
Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins.
Topics: Antineoplastic Agents, Hormonal; Cell Division; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Phosphorylation; Piperidines; Raloxifene Hydrochloride; Receptor, IGF Type 1; Tamoxifen; Tumor Cells, Cultured; Tyrosine | 1996 |
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Topics: Adipose Tissue; Animals; Bone Density; Estrogen Antagonists; Estrogens; Female; Lipid Metabolism; Nafoxidine; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reproduction; Tamoxifen; Uterus | 1996 |
Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Estrogen Antagonists; Female; Humans; Lavandula; Male; Neoplasms; Oils, Volatile; Ovarian Neoplasms; Piperidines; Plant Oils; Plants, Medicinal; Prostatic Neoplasms; Raloxifene Hydrochloride; Retinoids; Tamoxifen; Toremifene | 1996 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1996 |
Estrogen and bone: new pieces to the puzzle.
Topics: Animals; Bone Resorption; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Humans; Mice; Osteoblasts; Osteoclasts; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor beta | 1996 |
Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones.
Topics: Calcitriol; Creatine Kinase; Endometrium; Estradiol; Estrogen Antagonists; Female; Humans; Osteoblasts; Piperidines; Plasmids; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Recombinant Proteins; Stimulation, Chemical; Tamoxifen; Teriparatide; Tumor Cells, Cultured | 1996 |
Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Topics: Animals; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Leiomyoma; Phenotype; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterine Neoplasms | 1996 |
Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Topics: Adipocytes; Age Factors; Animals; Anticarcinogenic Agents; Biomarkers; Bone and Bones; Cartilage; Cells, Cultured; Creatine Kinase; Dose-Response Relationship, Drug; Embryo, Mammalian; Epiphyses; Estradiol; Estrogen Antagonists; Female; Humans; Isoenzymes; Male; Osteoblasts; Piperidines; Puberty; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tamoxifen; Uterus | 1996 |
Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels.
Topics: Animals; Cholesterol; Dexamethasone; Disease Models, Animal; Estradiol; Estrogen Antagonists; Estrogens; Ethinyl Estradiol; Female; Fulvestrant; Lipids; Ovariectomy; Piperidines; Progesterone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1997 |
Estrogen receptor ligands modulate its interaction with DNA.
Topics: DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Ethinyl Estradiol; Fulvestrant; Humans; Ligands; Piperidines; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Tamoxifen; Transcription Factors | 1997 |
FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Diethylstilbestrol; DNA Nucleotidyltransferases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Hexestrol; HSP90 Heat-Shock Proteins; Humans; Ligands; Molecular Sequence Data; Nafoxidine; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Time Factors; Yeasts | 1997 |
Osteoporosis drugs show early promise.
Topics: Bone Density; Estrogen Antagonists; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1997 |
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Topics: Adenocarcinoma; Alkaline Phosphatase; Benzopyrans; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Proteins; Piperidines; Propionates; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Tumor Cells, Cultured | 1997 |
Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
Topics: Animals; Bone and Bones; Bone Density; Cinnamates; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Stilbenes; Tamoxifen; Tumor Cells, Cultured; Uterus | 1997 |
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
Topics: Animals; Breast Neoplasms; Cell Line; Diethylstilbestrol; Enhancer Elements, Genetic; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; HeLa Cells; Humans; Ligands; Piperidines; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Uterus | 1997 |
Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.
Topics: Alkaline Phosphatase; Carcinoma, Hepatocellular; Clone Cells; Estradiol; Estradiol Congeners; Estrogen Antagonists; Ethinyl Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Kinetics; Liver Neoplasms; Piperidines; Placenta; Pregnancy; Protein Biosynthesis; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Sex Hormone-Binding Globulin; Tamoxifen; Tetradecanoylphorbol Acetate; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1997 |
Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study.
Topics: Animals; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; In Situ Hybridization; Piperidines; Preoptic Area; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Progesterone; RNA, Messenger; Sensitivity and Specificity; Tamoxifen; Time Factors | 1997 |
Molecular determinants of tissue selectivity in estrogen receptor modulators.
Topics: Animals; Cell Line; Estradiol Congeners; Estrogen Antagonists; Female; Ligands; Models, Molecular; Molecular Conformation; Piperidines; Protein Conformation; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen; Thermodynamics; Tissue Distribution; Uterus | 1997 |
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Piperidines; Plasminogen Activator Inhibitor 1; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1998 |
Anti-estrogens come of age: a pioneer looks back.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms | 1998 |
Of designer drugs, magic bullets, and gold standards.
Topics: Cardiovascular Diseases; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Humans; Piperidines; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 1998 |
Tamoxifen, raloxifene findings unlikely to encourage genetic screening for breast cancer.
Topics: BRCA2 Protein; Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Genes, BRCA1; Genetic Testing; Humans; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transcription Factors | 1998 |
The prevention pill.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
Clear thinking on tamoxifen.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
Breast cancer biology blossoms in the clinic.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Tamoxifen; Trastuzumab | 1998 |
Until there's more information, caution advised in using tamoxifen or raloxifene for breast cancer prevention.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
In search of the perfect SERM: beyond tamoxifen and raloxifene.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1998 |
Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells.
Topics: Analysis of Variance; Androgen Antagonists; Antibodies, Monoclonal; Cell Division; Cell Line; Cells, Cultured; Creatine Kinase; Dihydrotestosterone; DNA; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Flutamide; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Microscopy, Fluorescence; Muscle, Smooth, Vascular; Piperidines; Platelet-Derived Growth Factor; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Thymidine | 1998 |
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
Topics: Diethylstilbestrol; Dimerization; DNA Nucleotidyltransferases; Estradiol; Estrogen Antagonists; Fulvestrant; Hexestrol; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen | 1998 |
New hope for prevention, treatment of breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1998 |
Designer estrogens.
Topics: Breast Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen | 1998 |
Tamoxifen debate hinges on whose risk is high enough.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Decision Making; Estrogen Antagonists; Female; Humans; Physician's Role; Piperidines; Raloxifene Hydrochloride; Risk; Tamoxifen | 1998 |
Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women.
Topics: Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 1998 |
Tamoxifen for prevention of breast cancer.
Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis | 1999 |
Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding.
Topics: Animals; Autoanalysis; Biotransformation; Chromatography, Liquid; In Vitro Techniques; Mass Spectrometry; Microsomes, Liver; Pharmaceutical Preparations; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Drug; Structure-Activity Relationship; Tamoxifen | 1999 |
[Bone and hormones. Estrogens and antiestrogens: action on osteoporosis].
Topics: Aged; Clinical Trials, Phase III as Topic; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipids; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Tamoxifen; Time Factors | 1999 |
Using SERMS for treating postmenopausal symptoms.
Topics: Aged; Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 1999 |
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 5: Selective estrogen receptor modulators and hormone replacement therapy. Proceedings of a conference. Charlottesville, Virginia, USA. September 21-23, 1997.
Topics: Antineoplastic Agents; Bone Density; Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Menopause; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Survivors; Tamoxifen | 1999 |
Encouraging news from the SERM frontier. Selective estrogen receptor modulator.
Topics: Estrogen Antagonists; Estrogens; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Tamoxifen | 1999 |
Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Topics: Animals; Anticarcinogenic Agents; Bromodeoxyuridine; Cell Division; Cell Nucleus; Dose-Response Relationship, Drug; Endometrium; Epithelium; Estradiol; Estrogens; Female; Hypertrophy; Mice; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Uterus; Vagina | 1999 |
Experts debate drugs for healthy women with breast cancer risk.
Topics: Adult; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Piperidines; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen | 1999 |
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist.
Topics: Amino Acid Sequence; Animals; Crystallography, X-Ray; Estrogen Receptor beta; Genistein; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Sequence Homology, Amino Acid; Tamoxifen | 1999 |
Exogenous estrogens, antiestrogens and lipid metabolism.
Topics: Anticholesteremic Agents; Contraindications; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hyperlipidemia, Familial Combined; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1999 |
Breast cancer highlights.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Neoplasm Staging; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 1999 |
Designer estrogens: breast cancer benefit, remaining questions.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1999 |
Preventing "unpreventable" cancers.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Mastectomy; Ovarian Neoplasms; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 1999 |
Sex steroid analogs.
Topics: Animals; Bone Resorption; Breast Neoplasms; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Hormones; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Tamoxifen | 1999 |
Reaping the benefits of designer estrogens.
Topics: Breast Neoplasms; Female; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
SERM: a new concept in the management of osteoporosis. Presentation.
Topics: Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Breast cancer hopes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Mammography; Raloxifene Hydrochloride; Tamoxifen | 1998 |
Women gain ground with BreastCare. Program ensures screening, treatment for poor.
Topics: Adult; Arkansas; Breast Neoplasms; Clinical Trials as Topic; Costs and Cost Analysis; Double-Blind Method; Estrogen Antagonists; Female; Humans; Mammography; Mass Screening; Medical Indigency; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Comparative analyses of mechanistic differences among antiestrogens.
Topics: Blood Proteins; Breast Neoplasms; Cell Division; Cinnamates; Drug Stability; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
Cancer. Genotyping treatments.
Topics: Estrogen Antagonists; Female; Genotype; Humans; Neoplasms; Raloxifene Hydrochloride; Signal Transduction; Tamoxifen | 2000 |
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Bone and Bones; Breast Neoplasms; Cholesterol; Estrogen Antagonists; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Organ Size; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reference Values; Tamoxifen; Toremifene; Transplantation, Heterologous; Tumor Cells, Cultured; Uterus | 2000 |
Estrogen synthesis in human colon cancer epithelial cells.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Colorectal Neoplasms; Estrogen Antagonists; Estrogens; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genistein; Humans; Kinetics; Quercetin; Raloxifene Hydrochloride; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 1999 |
Identification of selective estrogen receptor modulators by their gene expression fingerprints.
Topics: Animals; Bone Density; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Polyunsaturated Alkamides; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Estrogen; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transcortin; Tumor Cells, Cultured | 2000 |
Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex.
Topics: Animals; Carrier Proteins; Cell Line; COS Cells; Estradiol; Fulvestrant; Humans; Mediator Complex; Mediator Complex Subunit 1; Mutation; Nuclear Proteins; Peptide Fragments; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; Surface Plasmon Resonance; Tamoxifen; Trans-Activators; Transcription Factors; Transcriptional Activation; Transfection | 2000 |
Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Confidence Intervals; Disease Progression; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Receptors, Estrogen; Remission Induction; Safety; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen | 2000 |
The effect of raloxifene on the uterine weight response in immature mice exposed to 17beta-estradiol, 1,1,1-trichloro-2, 2-bis(p-chlorophenyl)ethane, and methoxychlor.
Topics: Animals; DDT; Drug Interactions; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Methoxychlor; Mice; Organ Size; Raloxifene Hydrochloride; Tamoxifen; Uterus | 2000 |
Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain.
Topics: Adjuvants, Immunologic; Animals; Brain; Dehydroepiandrosterone; Estradiol; Estrogen Antagonists; Female; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Estrogen; Receptors, Serotonin; Tamoxifen | 2000 |
A brief review of the current breast cancer prevention trials and proposals for future trials.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hot Flashes; Humans; Menstruation Disturbances; Meta-Analysis as Topic; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2000 |
Luteinizing hormone secretion elicited in a ligand-independent activation of progesterone receptor manner at pituitary level in the rat: differential effect of two selective estrogen receptor modulators.
Topics: Animals; Estrogen Receptor Modulators; Female; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Mifepristone; Pituitary Gland, Anterior; Pregnancy; Prolactin; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Progesterone; Tamoxifen | 2000 |
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
Topics: Allosteric Regulation; Amino Acid Substitution; Aspartic Acid; Binding Sites; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Glycine; Humans; Kinetics; Ligands; Mutagenesis, Site-Directed; Protein Conformation; Protein Structure, Tertiary; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2000 |
In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Carcinoma, Hepatocellular; Cholesterol; Humans; Lipid Metabolism; Lipoproteins, VLDL; Raloxifene Hydrochloride; Tamoxifen; Triglycerides; Tumor Cells, Cultured | 2000 |
Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
Topics: Animals; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Ligands; Mammary Glands, Animal; Osteoblasts; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Response Elements; Tamoxifen | 2000 |
Update on raloxifene to prevent endometrial-breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro.
Topics: Breast Neoplasms; Cell Division; Estrogen Antagonists; Estrogens; Female; Humans; Raloxifene Hydrochloride; Repressor Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2000 |
The oestrogen receptor and its selective modulators in gynaecological oncology.
Topics: Antineoplastic Agents, Hormonal; Cinnamates; Estrogen Antagonists; Female; Genital Neoplasms, Female; Humans; Norpregnenes; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thiophenes; Toremifene | 2000 |
[Biochemical mechanism of raloxifen and tamoxifen action for the prevention of breast cancer. Studies in vitro].
Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2000 |
Estrogenic activity of tamoxifen and raloxifene on rat brain AMPA receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autoradiography; Binding, Competitive; Brain Chemistry; Estrogen Antagonists; Estrogens; Excitatory Amino Acid Agonists; Female; Frontal Lobe; Menopause; Organ Size; Ovariectomy; Radioligand Assay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Tamoxifen; Tritium; Uterus | 2001 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcitonin; Climacteric; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Heart Diseases; Humans; Menopause; Menopause, Premature; Neoplasm Recurrence, Local; Osteoporosis; Pregnancy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2001 |
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Topics: Allosteric Regulation; Breast Neoplasms; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Humans; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2001 |
Flexible alignment of small molecules.
Topics: Databases, Factual; Dipeptides; Estradiol; Folic Acid; Ligands; Methotrexate; Models, Molecular; Molecular Conformation; Proteins; Raloxifene Hydrochloride; Succinates; Tamoxifen | 2001 |
Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.
Topics: Cinnamates; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Genes, Regulator; HeLa Cells; Humans; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Transcription Factor AP-1; Transcription, Genetic | 2001 |
Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain.
Topics: Animals; Brain; Estradiol; Estrogen Antagonists; Estrogens; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Ovariectomy; Phenols; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tamoxifen | 2001 |
Tamoxifen and contralateral breast cancer: the other side.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Immunohistochemistry; Ligands; Middle Aged; Models, Statistical; Placebos; Raloxifene Hydrochloride; Receptors, Estrogen; Retrospective Studies; Risk; Tamoxifen; Time Factors | 2001 |
Adenomyosis--a result of disordered stromal differentiation.
Topics: Administration, Oral; Aging; Animals; Animals, Newborn; Body Weight; Calcium-Binding Proteins; Cell Differentiation; Endometriosis; Estradiol; Female; Gene Expression Regulation; Growth Inhibitors; Insulin-Like Growth Factor II; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Myometrium; Nerve Growth Factor; Oligonucleotide Array Sequence Analysis; Organ Size; Raloxifene Hydrochloride; Repressor Proteins; Selective Estrogen Receptor Modulators; Stromal Cells; Tamoxifen; Toremifene; Uterus | 2001 |
Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres.
Topics: Amino Acid Motifs; Benzophenones; Cyclic AMP Response Element-Binding Protein; Estradiol; Estrogen Receptor beta; Histone Acetyltransferases; Humans; Ligands; Microspheres; Molecular Sequence Data; Nuclear Receptor Coactivator 1; Peptides; Protein Binding; Raloxifene Hydrochloride; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Tamoxifen; Transcription Factors; Tyrosine | 2001 |
Update in general internal medicine.
Topics: Breast Neoplasms; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomised rat uterus.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Culture Techniques; Creatine Kinase; Creatine Kinase, BB Form; Dose-Response Relationship, Drug; Estradiol; Female; Gene Expression Regulation; Isoenzymes; Oligonucleotide Array Sequence Analysis; Ornithine Decarboxylase; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Uterus | 2001 |
Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification.
Topics: Alkaline Phosphatase; Base Sequence; Bone and Bones; Branched DNA Signal Amplification Assay; Breast; Cell Line; Endothelium; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation; Glycoproteins; Humans; Inhibitory Concentration 50; Oligodeoxyribonucleotides; Osteoblasts; Osteoprotegerin; Raloxifene Hydrochloride; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Receptors, Progesterone; Receptors, Tumor Necrosis Factor; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transcriptional Activation; Uterus | 2001 |
The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes.
Topics: Amino Acid Sequence; Cell Line; Estrogen Antagonists; Estrogen Receptor alpha; Glutathione Transferase; Histone Deacetylases; Humans; Ligands; Luciferases; Models, Biological; Molecular Sequence Data; Mutation; Plasmids; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Transfection; Two-Hybrid System Techniques | 2001 |
Selective estrogen-receptor modulators in 2001.
Topics: Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pilot Projects; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis | 2001 |
Raloxifene and breast cancer.
Topics: Animals; Breast Neoplasms; Disease Models, Animal; Estrogen Antagonists; Female; Humans; Mice; Raloxifene Hydrochloride; Tamoxifen; Tumor Cells, Cultured | 2001 |
Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site.
Topics: Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; HeLa Cells; Humans; Ligands; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1 | 2001 |
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Nuclear Receptor Coactivator 2; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Transcription Factors; Transfection; Transforming Growth Factor alpha; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
New strategies for the treatment of breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Estrogen Receptor Modulators; Female; Humans; Mastectomy, Segmental; Prognosis; Raloxifene Hydrochloride; Survival Analysis; Tamoxifen; Treatment Outcome | 2001 |
The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Incidence; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; White People | 2001 |
Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
Topics: Amino Acid Substitution; Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Tumor Cells, Cultured | 2001 |
Recruitment of women into trials.
Topics: Anticarcinogenic Agents; Bias; Breast Neoplasms; Control Groups; Female; Humans; Patient Selection; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Subjects; Selective Estrogen Receptor Modulators; Sex Characteristics; Sex Factors; Tamoxifen; Women | 2002 |
Selective estrogen receptor modulator effects in the rat brain.
Topics: Amygdala; Animals; Body Weight; Brain; Carrier Proteins; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression; Hypothalamus; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Nerve Tissue Proteins; Ovariectomy; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; RNA, Messenger; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tamoxifen | 2002 |
Hormone replacement therapy trials: an update.
Topics: Coronary Disease; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Middle Aged; Phytoestrogens; Plant Preparations; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Hobson's choice and the need for combinations of new agents for the prevention and treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2002 |
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Breast cancer prevention.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Middle Aged; Multicenter Studies as Topic; Raloxifene Hydrochloride; Tamoxifen | 2002 |
Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells.
Topics: Blotting, Northern; Cells, Cultured; Chemokine CCL2; Coronary Vessels; Down-Regulation; Endothelium, Vascular; Estradiol; Female; Gene Expression Regulation; Humans; Middle Aged; Prospective Studies; Raloxifene Hydrochloride; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Umbilical Veins | 2002 |
Comparative effects of testosterone propionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat.
Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Differentiation; Chi-Square Distribution; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Hypothalamus; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone | 2002 |
Tamoxifen: a personal retrospective.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; History, 20th Century; History, 21st Century; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Biomedicine. Defining the "S" in SERMs.
Topics: Breast; Breast Neoplasms; DNA; Drug Resistance, Neoplasm; Estradiol; Estrogen Replacement Therapy; Female; Histone Acetyltransferases; Humans; Ligands; Macromolecular Substances; Nuclear Receptor Coactivator 1; Organ Specificity; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Uterine Neoplasms; Uterus | 2002 |
Molecular determinants for the tissue specificity of SERMs.
Topics: Breast; Breast Neoplasms; Cell Cycle; DNA-Binding Proteins; Endometrial Neoplasms; Endometrium; Estradiol; Female; Gene Expression Regulation; Gene Silencing; Genes, myc; Histone Acetyltransferases; Histone Deacetylases; Humans; Insulin-Like Growth Factor I; Nuclear Receptor Coactivator 1; Organ Specificity; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Repressor Proteins; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Upstaging tamoxifen? New classes of drugs emerging for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Double-Blind Method; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
A 60-year-old woman trying to discontinue hormone replacement therapy.
Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fibrocystic Breast Disease; Hot Flashes; Humans; Hysterectomy; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis | 2002 |
Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
Topics: Animals; Breast Neoplasms; Cell Division; Cell Size; Cinnamates; Endometrium; Epithelial Cells; Estrogen Antagonists; Estrone; Female; Humans; Kinetics; Mice; Mice, Nude; Neoplasm Transplantation; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Stilbenes; Tamoxifen; Toremifene; Tumor Cells, Cultured | 2002 |
Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Libido; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Time Factors; Vaginal Discharge; Weight Gain | 2002 |
Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells.
Topics: Animals; Cell Death; Cell Division; Cell Line; Cell Transplantation; Endometrium; Estradiol; Estrogen Antagonists; Female; Gene Expression Regulation; Genes, Reporter; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovariectomy; Progesterone; Promoter Regions, Genetic; Raloxifene Hydrochloride; Random Allocation; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic | 2002 |
Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Topics: Adenocarcinoma; Animals; Blotting, Northern; Cell Division; Endometrial Neoplasms; Endothelial Growth Factors; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Luciferases; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Proteins; Raloxifene Hydrochloride; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Trefoil Factor-1; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Topics: Animals; Cinnamates; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxyl or counterpart hydroxyl with histidine 524 of the human estrogen receptor alpha.
Topics: Alanine; Amino Acid Substitution; Animals; Binding Sites; COS Cells; Diethyl Pyrocarbonate; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Histidine; Humans; Hydroxyl Radical; Ligands; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2002 |
Chemoprevention of breast cancer: recommendations and rationale.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Evidence-Based Medicine; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Summaries for patients. Using medication to prevent breast cancer: recommendations from the United States Preventive Services Task Force.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Evidence-Based Medicine; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
USPSTF releases guidelines on breast-cancer chemoprevention.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; United States | 2002 |
Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Catalysis; Enzyme Activation; Epithelial Cells; Estrogen Antagonists; Humans; Phospholipase D; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2002 |
Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Fractionation; Cell Size; Estradiol; Estrogen Antagonists; Etoposide; Fulvestrant; Genes, Reporter; HeLa Cells; Humans; Microscopy, Electron; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Transcriptional Activation | 2002 |
Responsiveness of endometrial genes Connexin26, Connexin43, C3 and clusterin to primary estrogen, selective estrogen receptor modulators, phyto- and xenoestrogens.
Topics: Animals; Clusterin; Complement C3; Connexin 26; Connexin 43; Connexins; Diethylstilbestrol; Endometrium; Estrogens; Estrogens, Non-Steroidal; Female; Gene Expression Regulation; Glycoproteins; Isoflavones; Molecular Chaperones; Phytoestrogens; Plant Preparations; Polychlorinated Biphenyls; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Breast cancer prevention and surveillance.
Topics: Breast Neoplasms; Female; Humans; Incidence; Life Style; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators.
Topics: Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Genitalia, Female; Hot Flashes; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2002 |
Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
Topics: Advisory Committees; Age Factors; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Female; Humans; Practice Guidelines as Topic; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2002 |
Estrogen and selective estrogen receptor modulator regulation of insulin-like growth factor binding protein 5 in the rat uterus.
Topics: Animals; Base Sequence; DNA; Estrogens; Female; Insulin-Like Growth Factor Binding Protein 5; Molecular Sequence Data; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Uterus | 2002 |
Tamoxifen versus raloxifene in the prevention of breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2002 |
Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain.
Topics: Animals; Estrogen Antagonists; Female; Organ Size; Prosencephalon; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2002 |
Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Glutathione Transferase; HeLa Cells; Histone Deacetylases; Humans; Luciferases; Models, Biological; Models, Molecular; Mutation; Plasmids; Precipitin Tests; Progesterone; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection; Tumor Cells, Cultured | 2003 |
Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; DNA; Endometrial Neoplasms; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression; Humans; Luciferases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Response Elements; Tamoxifen; Transfection; Tumor Cells, Cultured | 2003 |
Differential effects of selective estrogen receptor modulators and estrogens on mammary blood flow in the ovine.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Estradiol; Estrogens; Estrogens, Conjugated (USP); Female; Heart Rate; Kinetics; Mammary Glands, Animal; Norpregnenes; Ovariectomy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sheep; Tamoxifen | 2002 |
ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).
Topics: Adult; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular System; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2002 |
Biological significance of interventions that change breast density.
Topics: Anticarcinogenic Agents; Breast; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Mammography; Middle Aged; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
The hidden alternative: getting investigational treatments off-study.
Topics: Biomedical Research; Breast Neoplasms; Female; Humans; Informed Consent; Patient Rights; Physician-Patient Relations; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; United States | 2003 |
Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United States | 2002 |
A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment.
Topics: Amino Acid Sequence; Cyclic AMP Response Element-Binding Protein; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Europium; Fluorescence Resonance Energy Transfer; Histone Acetyltransferases; Humans; Ligands; Molecular Sequence Data; Nuclear Receptor Coactivator 1; Oligopeptides; Peptides; Protein Binding; Raloxifene Hydrochloride; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Tamoxifen; Transcription Factors; Transcriptional Activation | 2003 |
Comparison of the effect of oestradiol, tamoxifen and raloxifene on nerve growth factor-alpha expression in specific neonatal mouse uterine cell types using laser capture microdissection.
Topics: Animals; Animals, Newborn; Base Sequence; Blotting, Western; DNA Primers; Estradiol; Female; Gene Expression Regulation; Immunohistochemistry; Lasers; Mice; Nerve Growth Factors; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2003 |
Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor.
Topics: Animals; Anxiety Disorders; Binding, Competitive; Brain; Depressive Disorder; Drug Administration Schedule; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Neurons; Ovariectomy; Radioligand Assay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; RNA, Messenger; Selective Estrogen Receptor Modulators; Serotonin; Tamoxifen | 2003 |
Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Breast Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Guanine; Humans; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xeroderma Pigmentosum Group A Protein | 2003 |
Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation.
Topics: Amino Acid Substitution; Base Sequence; Binding Sites; DNA; Estradiol; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Humans; In Vitro Techniques; Leucine; Ligands; Models, Molecular; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1; Transcriptional Activation; Two-Hybrid System Techniques | 2003 |
Chemoprevention of breast cancer: recommendations and rationale.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2003 |
Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
Topics: Animals; Cell Division; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation; Insulin-Like Growth Factor I; Ki-67 Antigen; Organ Size; Ovariectomy; Proliferating Cell Nuclear Antigen; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Somatotropin; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2003 |
Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Chorionic Gonadotropin, beta Subunit, Human; Estradiol; Estrogen Receptor Modulators; Female; Medroxyprogesterone Acetate; Melitten; Mice; Mice, Inbred BALB C; Raloxifene Hydrochloride; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 2003 |
[From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma].
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Dietary Fats; Estradiol; Estrogen Antagonists; Ethanol; Follow-Up Studies; Humans; Incidence; Insulin-Like Growth Factor I; Mastectomy; Middle Aged; Obesity; Osteoporosis; Ovariectomy; Placebos; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sports; Tamoxifen; Time Factors | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?
Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; Treatment Outcome | 2003 |
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms | 2003 |
Playing the old piano: another tune for endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Diethylstilbestrol; Disease Progression; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Male; Neoplasms, Hormone-Dependent; Ovariectomy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Treatment Outcome | 2003 |
Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins.
Topics: Acetyltransferases; Genes, Reporter; HeLa Cells; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 3; Oncogene Proteins; Raloxifene Hydrochloride; Recombinant Fusion Proteins; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Trans-Activators; Transcription Factors | 2004 |
Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Topics: Breast Neoplasms; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Genistein; Humans; Ligands; Nuclear Receptor Coactivator 3; Ovarian Neoplasms; Protein Isoforms; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors | 2004 |
Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.
Topics: Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2004 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms | 2003 |
[Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
Topics: Anticarcinogenic Agents; Aromatase; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrrolidines; Raloxifene Hydrochloride; Response Elements; Tamoxifen; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.
Topics: Animals; Base Sequence; DNA Primers; DNA Replication; Estrogen Receptor Modulators; Female; Gene Expression Regulation; Genes, fos; Organ Size; Polymerase Chain Reaction; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tamoxifen; Uterus; Vascular Endothelial Growth Factor A | 2004 |
Cloning and functional characterization of PELP1/MNAR promoter.
Topics: Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Co-Repressor Proteins; Codon, Initiator; DNA; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression; HeLa Cells; Humans; Luciferases; Molecular Sequence Data; Osteosarcoma; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; RNA, Messenger; Sequence Analysis, DNA; Tamoxifen; Trans-Activators; Transcription Factors | 2004 |
Effects of the selective estrogen receptor modulator LY117018 on growth hormone secretion: In vitro studies.
Topics: Adenoma; Adult; Aged; Animals; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Estradiol; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Pituitary Gland; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Secretory Rate; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2004 |
Differential effects of estradiol, raloxifene and tamoxifen on estrogen receptor expression in cultured human skin fibroblasts.
Topics: Cells, Cultured; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fibroblasts; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Skin; Tamoxifen | 2004 |
Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.
Topics: Animals; Binding Sites; Crystallization; Diethylstilbestrol; Dimerization; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens, Non-Steroidal; Mice; Models, Molecular; Peptide Fragments; Protein Conformation; Protein Structure, Secondary; Raloxifene Hydrochloride; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Recombinant Proteins; Tamoxifen | 2004 |
Refining clinical practice: transforming science research into the art of medicine.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Genes, BRCA1; Humans; Raloxifene Hydrochloride; Tamoxifen | 2004 |
Lead identification of a potent benzopyranone selective estrogen receptor modulator.
Topics: Animals; Binding Sites; Coumarins; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Interleukin-6; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Tumor Cells, Cultured | 2004 |
Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
Topics: Adolescent; Case-Control Studies; Gynecomastia; Humans; Male; Patient Satisfaction; Puberty; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2004 |
Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Cell Division; Cell Line, Tumor; Endometrial Neoplasms; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2004 |
Selective estrogen receptor modulators prevent neointima formation after vascular injury.
Topics: Animals; Aorta; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Estradiol; Estrogens; Female; Fulvestrant; Muscle, Smooth, Vascular; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Tunica Intima | 2004 |
Chronic estrogenic drug treatment increases preproenkephalin mRNA levels in the rat striatum and nucleus accumbens.
Topics: Analysis of Variance; Animals; Drug Administration Schedule; Enkephalins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gyrus Cinguli; Neostriatum; Nitriles; Nucleus Accumbens; Organ Size; Ovariectomy; Phenols; Prefrontal Cortex; Protein Precursors; Pyrazoles; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Uterus | 2005 |
The putative tumor suppressor deleted in malignant brain tumors 1 is an estrogen-regulated gene in rodent and primate endometrial epithelium.
Topics: Agglutinins; Alu Elements; Animals; Blotting, Northern; Calcium-Binding Proteins; Cell Differentiation; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endometrium; Epithelium; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Haplorhini; Humans; Immunohistochemistry; Luciferases; Mucins; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; RNA; Tamoxifen; Transfection; Tumor Suppressor Proteins; Up-Regulation; Uterus | 2005 |
Raloxifene rebound regression.
Topics: Antineoplastic Agents; Bone Diseases, Metabolic; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Doxorubicin; Estrogen Antagonists; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Raloxifene Hydrochloride; Remission Induction; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures.
Topics: Amyloid beta-Peptides; Apoptosis; Cell Division; Cell Survival; Cells, Cultured; DNA-Binding Proteins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Expression; Humans; Nerve Tissue Proteins; Neurons; Oxidative Stress; Oxidoreductases Acting on CH-CH Group Donors; Raloxifene Hydrochloride; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Telomerase | 2005 |
Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Topics: Cells, Cultured; Endometrium; Epithelial Cells; Estradiol; Female; Gene Expression; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Raloxifene Hydrochloride; RNA; Selective Estrogen Receptor Modulators; Stromal Cells; Tamoxifen | 2005 |
Repercussions of raloxifen, tamoxifen and estrogen on aortic atherosclerotic lesions of female rabbits submitted to ovariectomy and hypercholesterol diet.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Diet, Atherogenic; Estrogens; Estrogens, Conjugated (USP); Female; Image Processing, Computer-Assisted; Models, Animal; Ovariectomy; Photography; Prospective Studies; Rabbits; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triglycerides | 2005 |
Gonadotrope oestrogen receptor-alpha and -beta and progesterone receptor immunoreactivity after ovariectomy and exposure to oestradiol benzoate, tamoxifen or raloxifene in the rat: correlation with LH secretion.
Topics: Animals; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Immunohistochemistry; Luteinizing Hormone; Ovariectomy; Ovary; Pituitary Gland; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogens; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Humans; Luciferases; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Ovary; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Time Factors; Transcriptional Activation; Treatment Outcome; Uterus | 2005 |
Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen.
Topics: Cell Division; Cell Survival; Collagen; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Drug Combinations; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Laminin; Ovarian Neoplasms; Phosphoproteins; Proteoglycans; Raloxifene Hydrochloride; Tamoxifen; Tumor Cells, Cultured | 2005 |
Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures.
Topics: Aged; Antineoplastic Agents, Hormonal; Cell Culture Techniques; Estradiol; Estrogen Antagonists; Female; Humans; Insulin-Like Growth Factor I; Interleukin-6; Middle Aged; Osteoblasts; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; RNA, Messenger; Tamoxifen; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoradiography; Brain Chemistry; Estrogen Antagonists; Female; GTP-Binding Proteins; Organ Size; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Tamoxifen | 2005 |
Effect of tamoxifen, raloxifen and tibolon on bile components in ovariectomized rats.
Topics: Animals; Bile; Bile Acids and Salts; Calcium; Chlorides; Cholesterol; Female; Norpregnenes; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tamoxifen | 2005 |
Treatment of adolescents with gynecomastia.
Topics: Adolescent; Gynecomastia; Humans; Male; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Blotting, Northern; Cell Proliferation; Cells, Cultured; CpG Islands; DNA; Dose-Response Relationship, Drug; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Estradiol; Fulvestrant; Hippocampus; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inflammation; Interleukin-6; L-Lactate Dehydrogenase; Lipopolysaccharides; Mice; Microglia; Nitric Oxide; Oligonucleotides; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Wistar; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2005 |
Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA, Complementary; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation, Missense; Ovariectomy; Raloxifene Hydrochloride; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Transfection; Xenograft Model Antitumor Assays | 2005 |
Effect of tamoxifen and raloxifene on cholesterol transformation to bile acids in ovariectomized rats.
Topics: Animals; Bile; Bile Acids and Salts; Cholesterol; Female; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation.
Topics: Adjuvants, Immunologic; Animals; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Dendritic Cells; Estradiol; Female; Growth Inhibitors; Immune Tolerance; Immunosuppressive Agents; Lipopolysaccharides; Male; Mice; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toll-Like Receptor 4 | 2005 |
Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Carcinoma; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred SENCAR; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
A short-incubation reporter-gene assay for high-throughput screening of estrogen receptor-alpha antagonists.
Topics: Animals; beta-Lactamases; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fluorescence Resonance Energy Transfer; Fulvestrant; Genetic Vectors; Raloxifene Hydrochloride; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Transcriptional Activation; Transfection | 2005 |
Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Topics: Amphiregulin; Antineoplastic Agents, Hormonal; EGF Family of Proteins; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
Women's decision making about whether or not to use breast cancer chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Breast Neoplasms; California; Chemoprevention; Decision Making; Female; Humans; Middle Aged; Patient Education as Topic; Raloxifene Hydrochloride; Risk Assessment; Surveys and Questionnaires; Tamoxifen; Women's Health | 2005 |
Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line.
Topics: Animals; Astrocytes; Blotting, Western; Cell Line; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Expression Regulation; Ligands; Luciferases; Mice; Neuroglia; Oligodendroglia; Plasmids; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Transfection | 2005 |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
Topics: Breast Neoplasms; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Mammary Glands, Human; Mutation; Oligonucleotide Array Sequence Analysis; Protein Binding; Raloxifene Hydrochloride; Receptor Cross-Talk; Response Elements; Signal Transduction; Tamoxifen; Transcription Factors | 2005 |
Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases.
Topics: Binding Sites; Cloning, Molecular; Cytosol; Endometrium; Escherichia coli; Estrogen Antagonists; Female; Humans; In Vitro Techniques; Liver; Raloxifene Hydrochloride; Sulfotransferases; Tamoxifen | 2006 |
Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Contraceptive Agents, Female; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Humans; Medroxyprogesterone Acetate; Norethindrone; Norethindrone Acetate; Norpregnenes; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2005 |
Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups.
Topics: Adult; Aged; Attitude to Health; Breast Neoplasms; Ethnicity; Genetic Testing; Humans; Interviews as Topic; Logistic Models; Middle Aged; Multivariate Analysis; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; White People; Women | 2006 |
Three-dimensional models of non-steroidal ligands: a comparative molecular field analysis.
Topics: Binding Sites; Binding, Competitive; Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Estrogens; Female; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship; Raloxifene Hydrochloride; Receptors, Estrogen; Reproducibility of Results; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium.
Topics: Adult; Endometrium; Enzyme Activation; Estradiol; Estrogens; Female; Humans; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Raloxifene Hydrochloride; Tamoxifen | 2006 |
The future of women of minority race/ethnicity in breast cancer chemoprevention therapy.
Topics: Adult; Antineoplastic Agents, Hormonal; Black or African American; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States | 2006 |
Chemoprevention of breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
Topics: Acetyltransferases; Alleles; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 3; Oncogene Proteins; Peptides; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Thiophenes; Trans-Activators | 2006 |
Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.
Topics: Aspartic Acid; Cell Line; Estrogen Antagonists; Estrogen Receptor alpha; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2006 |
Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
Topics: Breast Neoplasms; Female; Humans; Incidence; Neoplasm Invasiveness; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
A better option?
Topics: Breast Neoplasms; Choice Behavior; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Uncertainty | 2006 |
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Neoplasm Staging; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Urinary Bladder Neoplasms | 2006 |
Selective estrogen receptor modulators and prevention of invasive breast cancer.
Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Contraindications; Controlled Clinical Trials as Topic; Drug Approval; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome; United States; United States Food and Drug Administration; Uterine Neoplasms | 2006 |
Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Inhibitory Concentration 50; Ligands; Models, Molecular; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Styrenes; Tamoxifen | 2006 |
On-line formation, separation, and estrogen receptor affinity screening of cytochrome P450-derived metabolites of selective estrogen receptor modulators.
Topics: Animals; Automation; Bioreactors; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Estrogen Receptor alpha; In Vitro Techniques; Kinetics; Liver; Mass Spectrometry; Microsomes, Liver; Molecular Structure; Raloxifene Hydrochloride; Rats; Reproducibility of Results; Selective Estrogen Receptor Modulators; Swine; Tamoxifen | 2006 |
The changing perspective on breast cancer and chemotherapy. Three new developments are better able to predict breast cancer recurrence and chemotherapy effectiveness.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2006 |
Raloxifene works as well as tamoxifen in preventing invasive breast cancer.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
A STAR is born.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2006 |
STAR trial reports.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Estrogen Antagonists; Female; Humans; Multicenter Studies as Topic; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen | 2006 |
Editorial: The SERM of my dreams.
Topics: Bone Density; Breast Neoplasms; Coronary Disease; Female; Humans; Osteoporosis; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Selective estrogen receptor modulators (SERMS).
Topics: Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2006 |
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Prohibitins; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Uterine Neoplasms | 2007 |
Raloxifene vs tamoxifen.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Topics: Animals; Estrogens; Ethinyl Estradiol; Female; Macaca fascicularis; Mammary Glands, Animal; Ovariectomy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus; Vagina | 2007 |
Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases.
Topics: Breast Neoplasms; Cell Line, Tumor; Dactinomycin; Estrogen Antagonists; Estrogens; Human Growth Hormone; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Kidney; Protein Synthesis Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; STAT5 Transcription Factor; Suppressor of Cytokine Signaling Proteins; Tamoxifen | 2007 |
Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Back Pain; Estrogens; Fatigue; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prevalence; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Tamoxifen; United States | 2007 |
Bone builder vs. breast cancer.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
[Prevention of breast cancer 2007. New evidence?].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Estrogen Antagonists; Female; Humans; Mammography; Mass Screening; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Tamoxifen | 2007 |
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Topics: Breast Neoplasms; Carcinoma; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured; Up-Regulation | 2007 |
Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene.
Topics: CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Electrophoretic Mobility Shift Assay; Estradiol; Estrogen Receptor alpha; Gene Expression Regulation; Heat-Shock Proteins; Humans; Immunoblotting; Luciferases; Mutation; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-jun; Raloxifene Hydrochloride; Receptors, Immunologic; Recombinant Fusion Proteins; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors | 2007 |
Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain.
Topics: Animals; Brain; Brain Chemistry; Estradiol; Female; Luteinizing Hormone; Mood Disorders; Neurons; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tamoxifen | 2007 |
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Topics: Animals; Apoptosis; Bone Resorption; Cattle; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Dexamethasone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Monocytes; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Interest in breast cancer chemoprevention among older women.
Topics: Aged; Breast Neoplasms; Chemoprevention; Comorbidity; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen | 2008 |
Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Decision Making; Endometrial Neoplasms; Estrogen Antagonists; Female; Genetic Counseling; Genetic Predisposition to Disease; Health Knowledge, Attitudes, Practice; Health Status; Humans; Menopause; Middle Aged; Models, Biological; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen | 2007 |
Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Mice; Mice, Inbred BALB C; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transplantation, Heterologous; Treatment Outcome; Urogenital Neoplasms | 2007 |
Estrogens shield breast cancer cells.
Topics: Breast Neoplasms; Estrogens; Female; Gene Expression Regulation, Neoplastic; Granzymes; Humans; Immunologic Surveillance; Killer Cells, Natural; Raloxifene Hydrochloride; Receptors, Estrogen; Serpins; Tamoxifen | 2007 |
[Drug prevention and proper nutrition. Prevention of breast cancer as in coronary heart disease?].
Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
A reconsideration of tamoxifen use for breast cancer.
Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Follow-up of patients with early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2007 |
Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.
Topics: Binding Sites; Cell Line, Tumor; Chromatin Immunoprecipitation; Computational Biology; Estradiol; Estrogen Receptor alpha; Gene Expression Regulation; Humans; Introns; Luciferases; Promoter Regions, Genetic; Raloxifene Hydrochloride; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection | 2008 |
Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice.
Topics: Animals; Cytokines; Estradiol; Estrogen Antagonists; Female; Macrophages; Mice; Mice, Inbred C57BL; Neutrophils; Ovariectomy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Skin; Tamoxifen; Wound Healing | 2008 |
Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 2007 |
Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 2007 |
Projecting individualized absolute invasive breast cancer risk in African American women.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biopsy; Black or African American; Breast Neoplasms; Carcinoma, Ductal, Breast; Confounding Factors, Epidemiologic; Estrogen Receptor Modulators; Female; Forecasting; Humans; Incidence; Logistic Models; Mammography; Mass Screening; Middle Aged; Odds Ratio; Raloxifene Hydrochloride; Risk Assessment; SEER Program; Tamoxifen; United States; Women's Health | 2007 |
Hormone modulation: a novel therapeutic approach for women with severe mental illness.
Topics: Administration, Cutaneous; Adult; Antimanic Agents; Antipsychotic Agents; Clinical Trials as Topic; Cognition Disorders; Drug Therapy, Combination; Estradiol; Female; Humans; Middle Aged; Psychotic Disorders; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chi-Square Distribution; Estrogen Receptor Modulators; Europe; Female; Genes, BRCA1; Genes, BRCA2; Genetic Variation; Heterozygote; Humans; Mass Screening; Mastectomy; Middle Aged; Mutation; Ovariectomy; Population Surveillance; Primary Prevention; Raloxifene Hydrochloride; Research Design; Surveys and Questionnaires; Tamoxifen | 2008 |
Chemoprevention of breast cancer.
Topics: Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2008 |
Mechanism of collagen biosynthesis up-regulation in cultured leiomyoma cells.
Topics: Blotting, Western; Cells, Cultured; Collagen; Dipeptidases; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Estradiol; Female; Fulvestrant; Humans; Leiomyoma; Middle Aged; Myometrium; Raloxifene Hydrochloride; Tamoxifen; Up-Regulation | 2007 |
Tamoxifen: to use or not to use.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Etoposide; Humans; Interleukin-6; Osteoblasts; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs.
Topics: Animals; Anti-Inflammatory Agents; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Histocompatibility Antigens Class II; Lipopolysaccharides; Male; Microglia; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
Topics: Adult; Cell Proliferation; Endometrium; Estradiol; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Organ Culture Techniques; Raloxifene Hydrochloride; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Stromal Cells; Tamoxifen | 2008 |
Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.
Topics: Aged; Anticarcinogenic Agents; Case-Control Studies; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Odds Ratio; Raloxifene Hydrochloride; Risk; Risk Factors; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen | 2008 |
Toward optimal health: advances in breast cancer detection and management. Interview by Jodi R. Godfrey.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Mammography; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2008 |
To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Disease-Free Survival; Female; Humans; Incidence; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis.
Topics: Animals; Cell Proliferation; Cells, Cultured; Demyelinating Diseases; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Estrogen Receptor alpha; Female; Genes, MHC Class II; Immunity, Cellular; Lipopolysaccharides; Mice; Mice, Knockout; Mice, Transgenic; Myelin Proteins; Myelin Sheath; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; T-Lymphocytes; Tamoxifen | 2009 |
Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Topics: Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Gene Expression Regulation; Humans; Organ Specificity; Raloxifene Hydrochloride; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Cost-Benefit Analysis; Female; Humans; Japan; Markov Chains; Middle Aged; Neoplasm Invasiveness; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2009 |
Tamoxifen and raloxifene produce conditioned taste avoidance in female rats: a microstructural analysis of licking patterns.
Topics: Animals; Behavior, Animal; Body Weight; Conditioning, Operant; Drinking; Female; Humans; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Long-Evans; Selective Estrogen Receptor Modulators; Tamoxifen; Taste | 2009 |
Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression; Humans; Neovascularization, Pathologic; Raloxifene Hydrochloride; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Transcription Factors; Transfection; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A | 2009 |
Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene.
Topics: Cell Cycle; Cell Line; Cell Proliferation; Cluster Analysis; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Profiling; Humans; Male; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Osteoblasts; Raloxifene Hydrochloride; Reproducibility of Results; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells.
Topics: Estradiol; Gene Expression; Gene Expression Regulation; Humans; Muscle Cells; Muscle, Skeletal; Nuclear Receptor Co-Repressor 2; Nuclear Receptor Coactivator 1; Raloxifene Hydrochloride; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Effects of oestrogen agonists on human dermal fibroblasts in an in vitro wounding assay.
Topics: Aging; Cell Movement; DNA; Estrogen Receptor alpha; Estrogens; Female; Fibroblasts; Humans; In Vitro Techniques; Middle Aged; Models, Biological; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Skin; Tamoxifen; Wound Healing | 2009 |
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells.
Topics: Actins; Adolescent; Adult; Cell Movement; Cells, Cultured; Cytoskeleton; Endometrium; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Immunoblotting; Immunoprecipitation; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Young Adult | 2009 |
Antitumorigenic effects of tamoxifen, raloxifene and the combination on the development of breast tumors induced by mouse mammary carcinoma cells in balb/c-J female mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Raloxifene Hydrochloride; Survival Rate; Tamoxifen; Tumor Cells, Cultured | 2009 |
Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.
Topics: Animals; Cats; Cell Line; Chloroquine; Electrophysiology; Estrogen Antagonists; Heart Atria; Heart Ventricles; Humans; Ion Channel Gating; Ion Channels; Kinetics; Myocytes, Cardiac; Patch-Clamp Techniques; Phosphatidylinositol 4,5-Diphosphate; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Raloxifene Hydrochloride; Tamoxifen; Transfection | 2009 |
Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Cost-Benefit Analysis; Drug Costs; Estrogen Receptor Modulators; Evidence-Based Medicine; Female; Humans; Japan; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen | 2009 |
Exploration of endocrine-disrupting chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor candidate.
Topics: Adamantane; Diethylstilbestrol; Endocrine Disruptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Humans; Ligands; Luciferases; Models, Molecular; Phenols; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2009 |
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fenretinide; Humans; Raloxifene Hydrochloride; Tamoxifen | 2009 |
Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones.
Topics: Aging; Animals; Astrocytes; Brain; Brain Injuries; Estradiol; Estrogens; Female; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Vimentin | 2009 |
Estrogen and selective estrogen receptor modulators regulate vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in human endometrial stromal cells.
Topics: Adult; Endometrium; Estradiol; Female; Humans; Raloxifene Hydrochloride; RNA, Messenger; Selective Estrogen Receptor Modulators; Stromal Cells; Tamoxifen; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.
Topics: Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Drug Delivery Systems; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen | 2009 |
Expressions of vascular endothelial growth factor and nitric oxide synthase III in the thyroid gland of ovariectomized rats are upregulated by estrogen and selective estrogen receptor modulators.
Topics: Actins; Animals; Estradiol; Estrogens; Female; Immunohistochemistry; Microvessels; Nitric Oxide Synthase Type III; Organ Size; Ovariectomy; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Thyroid Gland; Up-Regulation; Uterus; Vascular Endothelial Growth Factors | 2010 |
Another selective estrogen-receptor modulator for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2010 |
An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.
Topics: Animals; Blotting, Western; Estradiol; Estrogens, Conjugated (USP); Female; Indoles; Mice; Mice, Inbred C57BL; Ovariectomy; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Transcription, Genetic | 2010 |
Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
Topics: Carcinoma; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Phosphorylation; Raloxifene Hydrochloride; RNA, Small Interfering; Signal Transduction; Tamoxifen; Thyroid Neoplasms | 2010 |
Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake.
Topics: Acetylcysteine; Amino Acid Transport System ASC; Antioxidants; Apoptosis; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Estradiol; Female; Gene Expression; Glutamine; Glutathione; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2011 |
CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.
Topics: Apoproteins; Breast Neoplasms; Chemoprevention; Cytochrome P-450 CYP3A; DNA Damage; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2010 |
Tamoxifen and raloxifene modulate gap junction coupling during early phases of retinoic acid-dependent neuronal differentiation of NTera2/D1 cells.
Topics: Cell Differentiation; Cell Line, Tumor; Connexin 43; Gap Junctions; Humans; Neurons; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Up-Regulation | 2010 |
Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Aging; Animals; Cell Line; Cell Proliferation; Estrogen Antagonists; Finasteride; Humans; Male; Models, Animal; Proliferating Cell Nuclear Antigen; Prostate; Prostatic Hyperplasia; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Two good choices to prevent breast cancer: great taste, less filling.
Topics: Adenocarcinoma; Breast Neoplasms; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Humans; Incidence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2010 |
The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.
Topics: Adenocarcinoma; Breast Neoplasms; Decision Support Techniques; Drug Utilization; Estrogens; Female; Humans; Incidence; Internet; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Patient Education as Topic; Physicians, Family; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).
Topics: Adenocarcinoma; Breast Neoplasms; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Incidence; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Papillomavirus Vaccines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Sample Size; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Cervical Neoplasms | 2010 |
Development and validation of a test for environmental estrogens: Checking xeno-estrogen activity by CXCL12 secretion in BREAST CANCER CELL LINES (CXCL-test).
Topics: Benzhydryl Compounds; Breast Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Dose-Response Relationship, Drug; Environmental Monitoring; Environmental Pollutants; Estradiol; Estrogen Receptor Modulators; Estrogens; Ethinyl Estradiol; Female; Genistein; Humans; Phenols; Raloxifene Hydrochloride; Tamoxifen; Time Factors | 2010 |
Third-generation SERMs may face uphill battle.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2010 |
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes | 2011 |
High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes.
Topics: Benzhydryl Compounds; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Endocrine Disruptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; HeLa Cells; Humans; Microscopy, Fluorescence; Phenols; Principal Component Analysis; Promoter Regions, Genetic; Raloxifene Hydrochloride; Reproducibility of Results; Tamoxifen | 2011 |
Prevention of breast cancer: the case for studying inhibition of IGF-1 actions.
Topics: Animals; Breast Neoplasms; Female; Humans; Insulin-Like Growth Factor I; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Somatostatin; Tamoxifen | 2011 |
In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugs.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Coumarins; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen | 2011 |
Reduction of stimulated sodium iodide symporter expression by estrogen receptor ligands in breast cancer cells.
Topics: Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Interactions; Estradiol; Female; Gene Expression Regulation, Neoplastic; Humans; Iodine Radioisotopes; Ligands; Mice; Mice, Inbred BALB C; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Symporters; Tamoxifen; Tretinoin; Xenograft Model Antitumor Assays | 2011 |
Estrogen receptor ligands counteract cognitive deficits caused by androgen deprivation in male rats.
Topics: Animals; Brain; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Male; Maze Learning; Nitriles; Orchiectomy; Phenols; Propionates; Pyrazoles; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Cell Line; Cell Proliferation; Cell Survival; Endothelial Cells; Estradiol; Estrogen Antagonists; Estrogens; Eye Proteins; Macaca mulatta; Nerve Growth Factors; Osmolar Concentration; Raloxifene Hydrochloride; Retinal Neovascularization; Retinal Vessels; Selective Estrogen Receptor Modulators; Serpins; Tamoxifen; Up-Regulation; Vascular Endothelial Growth Factors | 2011 |
Breast cancer prevention in high-risk women: searching for new options.
Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Genes, BRCA1; Genes, BRCA2; Heterozygote; Humans; Mastectomy; Mutation; Ovariectomy; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Topics: Aged; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Hispanic or Latino; Humans; Middle Aged; Raloxifene Hydrochloride; Tamoxifen | 2011 |
Breast cancer chemoprevention gets personal.
Topics: Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2011 |
The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.
Topics: Carcinoma; Cells, Cultured; DNA Adducts; Dose-Response Relationship, Drug; Drug Combinations; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Metabolic Networks and Pathways; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.
Topics: 14-3-3 Proteins; Apoptosis; Breast Neoplasms; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen | 2012 |
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Hyperplasia; Estrogen Antagonists; Female; Follow-Up Studies; Hot Flashes; Humans; Incidence; Leiomyoma; Middle Aged; Ovarian Cysts; Polyps; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms; Vaginal Discharge | 2011 |
Comparative study of tamoxifen and raloxifene on endometrial cell proliferation of female rats in persistent estrus.
Topics: Animals; Cell Proliferation; Endometrium; Estrus; Female; Immunohistochemistry; Ki-67 Antigen; Raloxifene Hydrochloride; Random Allocation; Rats; Regression Analysis; Selective Estrogen Receptor Modulators; Single-Blind Method; Tamoxifen | 2012 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
In vitro and in vivo molecular imaging of estrogen receptor α and β homo- and heterodimerization: exploration of new modes of receptor regulation.
Topics: Animals; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation; Genes, Reporter; HEK293 Cells; Humans; Luciferases, Firefly; Luciferases, Renilla; Mice; Mice, Nude; Molecular Imaging; Piperidines; Protein Multimerization; Protein Stability; Protein Structure, Tertiary; Pyrazoles; Raloxifene Hydrochloride; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transplantation, Heterologous | 2011 |
Antidepressive and anxiolytic activity of selective estrogen receptor modulators in ovariectomized mice submitted to chronic unpredictable stress.
Topics: Animals; Anxiety; Depression; Disease Models, Animal; Female; Immobility Response, Tonic; Maze Learning; Mice; Ovariectomy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Social Isolation; Stress, Psychological; Swimming; Tamoxifen | 2012 |
Diesel exhaust particulate extracts inhibit transcription of nuclear respiratory factor-1 and cell viability in human umbilical vein endothelial cells.
Topics: Cell Proliferation; Cell Survival; Cells, Cultured; Drug Antagonism; Electron Transport Complex IV; Estradiol; Human Umbilical Vein Endothelial Cells; Humans; Mitochondria; Nuclear Respiratory Factor 1; Particulate Matter; Raloxifene Hydrochloride; Resveratrol; Stilbenes; Tamoxifen; Transcription, Genetic; Vehicle Emissions | 2012 |
What is the significance of gynecologic symptoms in the participants in the NSABP study?
Topics: Breast Neoplasms; Female; Humans; Leiomyoma; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms | 2011 |
Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; England; Female; History, 20th Century; History, 21st Century; Humans; Mice; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Translational Research, Biomedical | 2011 |
Selective estrogen receptor modulators regulate dendritic spine plasticity in the hippocampus of male rats.
Topics: Animals; Brain; Dendritic Spines; Hippocampus; Male; Neuronal Plasticity; Neurons; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2012 |
Assessment of micronucleus frequency in the peripheral blood of female rats in persistent estrus treated with selective estrogen receptor modulators.
Topics: Animals; Estrus; Female; Micronuclei, Chromosome-Defective; Micronucleus Tests; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen | 2012 |
Effects of selective estrogen receptor modulators on allocentric working memory performance and on dendritic spines in medial prefrontal cortex pyramidal neurons of ovariectomized rats.
Topics: Animals; Behavior, Animal; Dendritic Spines; Estradiol; Female; Maze Learning; Memory, Short-Term; Ovariectomy; Prefrontal Cortex; Psychomotor Performance; Pyramidal Cells; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Synapses; Tamoxifen | 2012 |
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.
Topics: Adult; Aged; Body Mass Index; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Obesity; Postmenopause; Premenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Tamoxifen | 2012 |
A multiplexed screening method for agonists and antagonists of the estrogen receptor protein.
Topics: Estradiol Congeners; Estrogen Antagonists; Humans; Kinetics; Ligands; Protein Array Analysis; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2012 |
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemoprevention; Drug Utilization; Female; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Tamoxifen; United States | 2012 |
Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.
Topics: Animals; Cluster Analysis; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Genes; Genes, Neoplasm; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transcriptome | 2012 |
Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries.
Topics: Animals; Cell Differentiation; Chemical and Drug Induced Liver Injury; Estrogen Receptor alpha; Ethinyl Estradiol; Female; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Raloxifene Hydrochloride; RNA, Messenger; RNA, Small Interfering; Selective Estrogen Receptor Modulators; Tamoxifen; Up-Regulation | 2012 |
Exemestane for primary prevention of breast cancer in postmenopausal women.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2012 |
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Topics: Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Immediate-Early Proteins; MCF-7 Cells; Poly(ADP-ribose) Polymerases; Raloxifene Hydrochloride; S-Phase Kinase-Associated Proteins; Tamoxifen; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Preventive therapy for breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Middle Aged; Piperidines; Preventive Medicine; Pyrrolidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma; Cell Count; Combined Modality Therapy; Female; Humans; Mammography; Middle Aged; Neoplasm Invasiveness; Postmenopause; Predictive Value of Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 2012 |
The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoprevention; Female; Humans; Hyperplasia; Mammary Glands, Human; Middle Aged; Precancerous Conditions; Raloxifene Hydrochloride; Tamoxifen | 2012 |
Effects of tamoxifen and raloxifene on body and uterine weights of rats in persistent estrus.
Topics: Animals; Anovulation; Body Weight; Disease Models, Animal; Female; Organ Size; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2012 |
Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Barrett Esophagus; Cadherins; Cell Count; Cell Culture Techniques; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ki-67 Antigen; Male; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2013 |
Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial.
Topics: Adult; Affect; Aged; Antineoplastic Agents; Breast Neoplasms; Cognition; Depression; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen | 2013 |
Breast cancer facts.
Topics: Age Distribution; Breast Neoplasms; Breast Neoplasms, Male; Early Detection of Cancer; Estrogen Replacement Therapy; Exercise; Female; Humans; Male; Overweight; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen; United States | 2012 |
Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies.
Topics: Breast Neoplasms; Case-Control Studies; Computer Simulation; Female; Genome-Wide Association Study; Humans; Linkage Disequilibrium; Models, Genetic; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Sequence Analysis, DNA; Tamoxifen | 2013 |
Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
Topics: Cell Line, Tumor; DNA; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression; HeLa Cells; Hep G2 Cells; Humans; Indoles; Ligands; Mutation; Promoter Regions, Genetic; Protein Multimerization; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Transcriptional Activation | 2013 |
Breast cancer drugs should be offered to healthy but high risk women, US panel concludes.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk; Tamoxifen; United States | 2013 |
Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Caveolin 1; Cell Nucleus; Cell Proliferation; Cytoplasm; Disease Models, Animal; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Humans; Mice; Protein Binding; Protein Kinase C-alpha; Protein Transport; Raloxifene Hydrochloride; Tamoxifen; Xenograft Model Antitumor Assays | 2013 |
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
Topics: BRCA1 Protein; Breast Neoplasms; Cathepsins; DNA-Binding Proteins; Estrogen Receptor Modulators; Female; Genome-Wide Association Study; Humans; Polymorphism, Single Nucleotide; Precision Medicine; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2013 |
NICE recommends preventive drugs for breast cancer.
Topics: Academies and Institutes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2013 |
Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.
Topics: Adult; Aged; Biomedical Research; Breast Neoplasms; Decision Making; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2013 |
Selective estrogen receptor modulation prevents scoliotic curve progression: radiologic and histomorphometric study on a bipedal C57Bl6 mice model.
Topics: Animals; Bone Density; Disease Models, Animal; Disease Progression; Female; Mice; Mice, Inbred C57BL; Raloxifene Hydrochloride; Scoliosis; Selective Estrogen Receptor Modulators; Tamoxifen | 2014 |
Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Curcumin; Estradiol; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Genistein; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2014 |
Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling.
Topics: Animals; Biomechanical Phenomena; Calcium; Female; Mice; Muscle Contraction; Myocytes, Cardiac; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Sarcomeres; Tamoxifen | 2013 |
Effects of selective estrogen receptor modulators on plasma membrane estrogen receptors and catecholamine synthesis and secretion in cultured bovine adrenal medullary cells.
Topics: Acetylcholine; Adrenal Medulla; Animals; Calcium; Catecholamines; Cattle; Cell Membrane; Cells, Cultured; Dose-Response Relationship, Drug; Oocytes; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Sodium; Tamoxifen; Tyrosine; Xenopus | 2014 |
Summaries for patients. Using medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2013 |
Experts add second drug to breast cancer prevention regimen.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States; Women's Health | 2013 |
SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
Topics: Cell Transformation, Neoplastic; Cells, Cultured; Cytoprotection; Estradiol; Humans; Inactivation, Metabolic; Indoles; Mammary Glands, Human; MCF-7 Cells; Oxidants; Oxidative Stress; Piperidines; Raloxifene Hydrochloride; Reactive Oxygen Species; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Up-Regulation | 2014 |
Selective estrogen receptor modulators (SERMs) enhance neurogenesis and spine density following focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Dendritic Spines; Estradiol; Female; Infarction, Middle Cerebral Artery; Lateral Ventricles; Neurogenesis; Neuroprotective Agents; Raloxifene Hydrochloride; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Estrogens; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2014 |
Lowering your breast cancer risk. A daily pill can hold the key to prevention for some women.
Topics: Adult; Breast Neoplasms; Female; Genetic Predisposition to Disease; Humans; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen | 2014 |
Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.
Topics: Animals; Estrogen Receptor alpha; Estrogen Receptor beta; Male; Mice; Mice, Inbred C57BL; Prostatic Hyperplasia; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Urinary Bladder Diseases | 2015 |
Raloxifene inhibits cloned Kv4.3 channels in an estrogen receptor-independent manner.
Topics: Animals; Bone Density Conservation Agents; CHO Cells; Cloning, Molecular; Cricetulus; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Estrogen Antagonists; Ion Channel Gating; Kinetics; Kv Channel-Interacting Proteins; Membrane Potentials; Patch-Clamp Techniques; Potassium Channel Blockers; Raloxifene Hydrochloride; Real-Time Polymerase Chain Reaction; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shal Potassium Channels; Tamoxifen; Transfection | 2015 |
Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Fulvestrant; Inflammation; Male; Microglia; Neurons; Plasmids; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Estrogen; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Hep G2 Cells; Hepatocytes; Humans; Lipoproteins, LDL; Lovastatin; Lymphocytes; Male; Raloxifene Hydrochloride; Receptors, LDL; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Toremifene | 2015 |
Risk-benefit profiles of women using tamoxifen for chemoprevention.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Cohort Studies; Drug Administration Schedule; Estrogen Antagonists; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Odds Ratio; Primary Prevention; Puerto Rico; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; United States | 2015 |
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Humans; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Prognosis; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Comparative effects of estrogen, raloxifene and tamoxifen on endothelial dysfunction, inflammatory markers and oxidative stress in ovariectomized rats.
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents; Cytokines; Endothelium, Vascular; Estrogen Antagonists; Estrogens; Female; Inflammation; NG-Nitroarginine Methyl Ester; Ovariectomy; Oxidative Stress; Postmenopause; Raloxifene Hydrochloride; Rats; Rats, Wistar; Reactive Oxygen Species; Tamoxifen; Vasodilation | 2015 |
Twenty-five years of breast cancer risk models and their applications.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Density; Breast Neoplasms; Cause of Death; Counseling; Early Detection of Cancer; Female; Humans; Incidence; Mammary Glands, Human; Mammography; Mass Screening; Mastectomy; Middle Aged; Models, Statistical; Public Health; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; SEER Program; Selective Estrogen Receptor Modulators; Tamoxifen; United States; Unnecessary Procedures; White People | 2015 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats.
Topics: Acoustic Stimulation; Animals; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Estradiol; Estrogens; Female; Ovariectomy; Prepulse Inhibition; Raloxifene Hydrochloride; Random Allocation; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Automatic endpoint detection to support the systematic review process.
Topics: Algorithms; Blood Glucose; Comparative Effectiveness Research; Data Mining; Electronic Data Processing; Evidence-Based Medicine; Female; Humans; Insulin; Language; Linear Models; Linguistics; Machine Learning; Metformin; Natural Language Processing; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Support Vector Machine; Systematic Reviews as Topic; Tamoxifen; Uterus | 2015 |
Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis.
Topics: Catalysis; Cytosol; Estradiol; Fulvestrant; Hep G2 Cells; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Sulfates; Sulfotransferases; Tamoxifen | 2015 |
My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Decision Making; Estrogen Antagonists; Female; Health Knowledge, Attitudes, Practice; Humans; Interviews as Topic; Middle Aged; National Cancer Institute (U.S.); Probability; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States | 2015 |
Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study.
Topics: Adult; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Interviews as Topic; Middle Aged; Narration; Qualitative Research; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Sociology, Medical; Tamoxifen; Uncertainty | 2015 |
Differential effects of selective estrogen receptor modulators on the vagina and its supportive tissues.
Topics: Animals; Collagen; Dose-Response Relationship, Drug; Estrogens, Conjugated (USP); Female; Indoles; Mammary Glands, Animal; Raloxifene Hydrochloride; Random Allocation; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina | 2016 |
Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Topics: Breast Neoplasms; Cell Proliferation; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA, Small Interfering; Tamoxifen | 2015 |
Comparison of the Effects of the Selective Estrogen Receptor Modulators Ospemifene, Raloxifene, and Tamoxifen on Breast Tissue in Ex Vivo Culture.
Topics: Apoptosis; Biomarkers; Breast; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Paraffin Embedding; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Tissue Culture Techniques; Tissue Fixation | 2016 |
Improved specificity of hippocampal memory trace labeling.
Topics: Animals; Bacterial Proteins; Cell Count; Channelrhodopsins; Conditioning, Psychological; Estradiol; Fear; Fulvestrant; Hippocampus; Immunohistochemistry; Luminescent Proteins; Memory; Mice, Transgenic; Microscopy, Confocal; Models, Animal; Neurons; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Untranslated; Selective Estrogen Receptor Modulators; Tamoxifen | 2016 |
Affective forecasting and medication decision making in breast-cancer prevention.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemoprevention; Decision Making; Decision Support Techniques; Female; Follow-Up Studies; Forecasting; Humans; Intention; Medication Adherence; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen | 2016 |
Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma in Situ; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fallopian Tubes; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Mice; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Thiophenes; Transcriptome | 2016 |
Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo.
Topics: Aged; Apolipoproteins D; Apoptosis; Breast; Cell Proliferation; Estrogen Receptor alpha; Female; Humans; Middle Aged; Polymorphism, Genetic; Postmenopause; Raloxifene Hydrochloride; Receptors, Androgen; Selective Estrogen Receptor Modulators; Tamoxifen; Trefoil Factor-1 | 2016 |
Evaluation of Ki-67 antigen expression in the vaginal epithelium of castrated female rats treated with raloxifene and tamoxifen: a comparative study.
Topics: Animals; Cell Proliferation; Epithelial Cells; Female; Ki-67 Antigen; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina | 2016 |
Raloxifene and Tamoxifen Reduce PARP Activity, Cytokine and Oxidative Stress Levels in the Brain and Blood of Ovariectomized Rats.
Topics: Animals; Apoptosis; Brain; Cytokines; Erythrocytes; Estrogen Antagonists; Female; Mitochondria; Ovariectomy; Oxidative Stress; Poly(ADP-ribose) Polymerases; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tamoxifen | 2016 |
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2016 |
Neonatal exposure to SERMs disrupts neuroendocrine development and postnatal reproductive function through alteration of hypothalamic kisspeptin neurons in female rats.
Topics: Age Factors; Animals; Animals, Newborn; Body Weight; Developmental Disabilities; Disease Models, Animal; Endocrine System Diseases; Estradiol; Estrous Cycle; Female; Hormones; Hypothalamus; Kisspeptins; Neurons; Ovariectomy; Pregnancy; Progesterone; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen | 2016 |
Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation.
Topics: Adult; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Chemoprevention; Clinical Competence; Female; Humans; Male; Middle Aged; Physicians, Family; Qualitative Research; Raloxifene Hydrochloride; Tamoxifen; United Kingdom | 2016 |
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Humans; Middle Aged; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen | 2016 |
Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G; Biological Transport; Cholesterol; Cholesterol Esters; Diet, Western; Esterification; Estradiol; Feces; Fulvestrant; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; THP-1 Cells; Toremifene | 2016 |
A transgenic mouse model expressing an ERα folding biosensor reveals the effects of Bisphenol A on estrogen receptor signaling.
Topics: Animals; Benzhydryl Compounds; Biosensing Techniques; Carcinogens; Environmental Exposure; Estrogen Receptor alpha; Estrogens; Fibroblasts; Humans; Luminescent Measurements; Mice, Transgenic; Molecular Imaging; Phenols; Raloxifene Hydrochloride; Recombinant Fusion Proteins; Reproducibility of Results; Selective Estrogen Receptor Modulators; Tamoxifen | 2016 |
Ovariectomy-Induced Mitochondrial Oxidative Stress, Apoptosis, and Calcium Ion Influx Through TRPA1, TRPM2, and TRPV1 Are Prevented by 17β-Estradiol, Tamoxifen, and Raloxifene in the Hippocampus and Dorsal Root Ganglion of Rats.
Topics: Animals; Apoptosis; Calcium; Estradiol; Estrogen Antagonists; Female; Ganglia, Spinal; Hippocampus; Mitochondria; Ovariectomy; Oxidative Stress; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tamoxifen; TRPA1 Cation Channel; TRPM Cation Channels; TRPV Cation Channels | 2017 |
From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Drug Repositioning; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Klebsiella pneumoniae; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2017 |
Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Indoles; Male; Mice; Mice, Inbred C57BL; Orchiectomy; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone; Vitamin D | 2017 |
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fumarates; Humans; MCF-7 Cells; Molecular Targeted Therapy; NF-kappa B; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen | 2017 |
The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF-kB in estrogen-deficient rats.
Topics: Active Transport, Cell Nucleus; Animals; Atrial Natriuretic Factor; Body Weight; Estrogens; Female; Heart; Hemodynamics; Myocardium; NF-kappa B; Organ Size; Ovariectomy; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2017 |
What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women?
Topics: Breast Neoplasms; Chemoprevention; Decision Making; Female; Humans; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen | 2017 |
A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene.
Topics: Adult; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Practice Patterns, Physicians'; Prognosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Specialization; Surveys and Questionnaires; Tamoxifen | 2018 |
Long-Term Treatment of Tamoxifen and Raloxifene Alleviates Dystrophic Phenotype and Enhances Muscle Functions of FKRP Dystroglycanopathy.
Topics: Animals; Body Weight; Bone Density; Dystroglycans; Female; Glycosylation; Heart; Male; Mice, Inbred C57BL; Muscles; Muscular Dystrophy, Animal; Organ Specificity; Pentosyltransferases; Phenotype; Proteins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Transferases | 2018 |
The effect of estrogenic compounds on psychosis-like behaviour in female rats.
Topics: Animals; Apomorphine; Dopamine Agonists; Estradiol; Estrogens; Female; Ovariectomy; Psychotic Disorders; Raloxifene Hydrochloride; Rats; Rats, Long-Evans; Receptors, Dopamine; Schizophrenia; Selective Estrogen Receptor Modulators; Tamoxifen | 2018 |
Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
Topics: Aged; Breast Neoplasms; Carcinoma; Chemoprevention; Cohort Studies; Estrogen Antagonists; Female; Humans; Medicare; Medicare Part D; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States | 2018 |
Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; England; Female; Guideline Adherence; Humans; Interrupted Time Series Analysis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Tamoxifen | 2018 |
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2018 |
Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
Topics: Adult; Aged; Breast Neoplasms; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Prognosis; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen | 2019 |
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2019 |
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Making, Shared; Female; Humans; Middle Aged; Physician-Patient Relations; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.
Topics: Australia; Breast Neoplasms; Cross-Sectional Studies; Decision Making; Female; General Practice; Health Communication; Humans; Logistic Models; Patient Education as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen | 2019 |
Breast Cancer Risk-Reducing Medications.
Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Estrogens; Female; Lipids; Menopause; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Streptozocin; Tamoxifen | 2020 |
Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues.
Topics: Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Breast; Cell Line, Tumor; Central Nervous System; Corpus Striatum; Drugs, Chinese Herbal; Estradiol; Estrogens; Female; Herb-Drug Interactions; Hormones; Humans; Mammary Glands, Human; Medicine, Chinese Traditional; Models, Biological; Ovariectomy; Raloxifene Hydrochloride; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus; Water | 2021 |
Breast Cancer Prevention: Time for Change.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen | 2021 |
Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Humans; Molecular Structure; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2021 |
[Recent Trends in Chemoprevention of Cancer].
Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2021 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estrogen Receptor alpha; Humans; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Protein Binding; Proteolysis; Raloxifene Hydrochloride; Reactive Oxygen Species; Sesterterpenes; Signal Transduction; Structure-Activity Relationship; Tamoxifen | 2022 |
SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Estrogen Receptor beta; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Indoles; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2022 |
Protective effects of combining SERMs with estrogen on metabolic parameters in postmenopausal diabetic cardiovascular dysfunction: The role of cytokines and angiotensin II.
Topics: Angiotensin II; Animals; Cytokines; Diabetes Mellitus, Type 2; Estrogens; Female; Interleukin-10; Postmenopause; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Necrosis Factor-alpha | 2022 |
Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Humans; Male; Raloxifene Hydrochloride; Tamoxifen | 2022 |
Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.
Topics: Animals; Antimalarials; Female; Heme; Hemeproteins; Hemoglobins; Humans; Indoles; Malaria; Malaria, Falciparum; Male; Mice; Neoplasms; Osteoporosis, Postmenopausal; Plasmodium falciparum; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2022 |
Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration.
Topics: Aged; Brain; Breast Neoplasms; Cognition; Cognitive Dysfunction; Cross-Sectional Studies; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2023 |
Cardioprotective effect of tamoxifen and raloxifene: Preventing proteoglycan synthesis by modulating non-canonical TGF-β signalling through NADPH oxidase and ERK phosphorylation.
Topics: Atherosclerosis; Humans; NADPH Oxidases; Phosphorylation; Proteoglycans; Raloxifene Hydrochloride; Reactive Oxygen Species; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transforming Growth Factor beta | 2023 |
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genes, BRCA1; Humans; Mutation; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2023 |
The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation.
Topics: Animals; Down-Regulation; Estrogen Receptor alpha; Humans; Macrophages; Mice; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2023 |